EP1467982B1 - Glucocorticoid mimetika, verfahren zu ihrer herstellung, pharmazeutische formulierungen sie enthaltend und verwendungen davon - Google Patents

Glucocorticoid mimetika, verfahren zu ihrer herstellung, pharmazeutische formulierungen sie enthaltend und verwendungen davon Download PDF

Info

Publication number
EP1467982B1
EP1467982B1 EP03701228A EP03701228A EP1467982B1 EP 1467982 B1 EP1467982 B1 EP 1467982B1 EP 03701228 A EP03701228 A EP 03701228A EP 03701228 A EP03701228 A EP 03701228A EP 1467982 B1 EP1467982 B1 EP 1467982B1
Authority
EP
European Patent Office
Prior art keywords
hydroxy
amide
oxo
fluoro
dihydroisobenzofuran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP03701228A
Other languages
English (en)
French (fr)
Other versions
EP1467982B8 (de
EP1467982A1 (de
Inventor
Raj Boehringer Ingelheim Corp. BETAGERI
David Boehringer Ingelheim Corp. THOMSON
Yan Boehringer Ingelheim Corp. ZHANG
Renee M. Boehringer Ingelheim Corp. ZINDELL
Mathew Danger Traini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharmaceuticals Inc
Publication of EP1467982A1 publication Critical patent/EP1467982A1/de
Application granted granted Critical
Publication of EP1467982B1 publication Critical patent/EP1467982B1/de
Publication of EP1467982B8 publication Critical patent/EP1467982B8/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/02—1,2-Oxazines; Hydrogenated 1,2-oxazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3

Definitions

  • the present invention relates to glucocorticoid mimetics or ligands, methods of making such compounds, their use in pharmaceutical compositions, and their use in modulating the glucocorticoid receptor function, treating disease-states or conditions mediated by the glucocorticoid receptor function in a patient in need of such treatment, and other uses.
  • Glucocorticoids a class of corticosteroids, are endogenous hormones with profound effects on the immune system and multiple organ systems. They suppress a variety of immune and inflammatory functions by inhibition of inflammatory cytokines such as IL-1, IL-2, IL-6, and TNF, inhibition of arachidonic acid metabolites including prostaglandins and leukotrienes, depletion of T-lymphocytes, and reduction of the expression of adhesion molecules on endothelial cells (P.J. Barnes, Clin. Sci., 1998, 94 , pp. 557-572; P.J. Barnes et al., Trends Pharmacol. Sci., 1993, 14 , pp. 436-441). In addition to these effects, glucocorticoids stimulate glucose production in the liver and catabolism of proteins, play a role in electrolyte and water balance, reduce calcium absorption, and inhibit osteoblast function.
  • glucocorticoids The anti-inflammatory and immune suppressive activities of endogenous glucocorticoids have stimulated the development of synthetic glucocorticoid derivatives including dexamethasone, prednisone, and prednisolone (L. Parente, Glucocorticoids , N.J. Goulding and R.J. Flowers (eds.), Boston: Birkhauser, 2001, pp. 35-54).
  • rheumatic diseases such as rheumatoid arthritis, juvenile arthritis, and ankylosing spondylitis
  • dermatological diseases including psoriasis and pemphigus
  • allergic disorders including allergic rhinitis, atopic dermatitis, and contact dermatitis
  • pulmonary conditions including asthma and chronic obstructive pulmonary disease (COPD)
  • COPD chronic obstructive pulmonary disease
  • Crohn disease ulcerative colitis
  • systemic lupus erythematosus autoimmune chronic active hepatitis, osteoarthritis, tendonitis, and bursitis
  • Glucocorticoids N.J. Goulding and R.J. Flowers (eds.), Boston: Birkhauser, 2001, pp. 161-174). They have also been used to help prevent rejection in organ transplantation.
  • glucocorticoids Unfortunately, in addition to the desired therapeutic effects of glucocorticoids, their use is associated with a number of adverse side effects, some of which can be severe and life-threatening. These include alterations in fluid and electrolyte balance, edema, weight gain, hypertension, muscle weakness, development or aggravation of diabetes mellitus, and osteoporosis. Therefore, a compound that exhibited a reduced side effect profile while maintaining the potent anti-inflammatory effects would be particularly desirable, especially when treating a chronic disease.
  • glucocorticoid receptor The glucocorticoid receptor is a member of a class of structurally related intracellular receptors that when coupled with a ligand can function as a transcription factor that affects gene expression (R.M. Evans, Science, 1988, 240, pp. 889-895).
  • Other members of the family of steroid receptors include the mineralocorticoid, progesterone, estrogen, and androgen receptors.
  • glucocorticoids In addition to the effects mentioned above for glucocorticoids, hormones that act on this receptor family have a profound influence on body homeostasis, mineral metabolism, the stress response, and development of sexual characteristics. Glucocorticoids , N.J. Goulding and R.J. Flowers (eds.), Boston: Birkhauser, 2001, describe the state of the art.
  • transactivation the translocation of the ligand-bound glucocorticoid receptor to the nucleus is followed by binding to glucocorticoid response elements (GREs) in the promoter region of side effect-associated genes, for example, phosphoenolpyruvate carboxy kinase (PEPCK) in the case of increased glucose production.
  • GREs glucocorticoid response elements
  • PEPCK phosphoenolpyruvate carboxy kinase
  • the anti-inflammatory effects are thought to be due to a process called transrepression.
  • transrepression is a process independent of DNA binding that results from inhibition of NF-kB and AP-1-mediated pathways, leading to down regulation of many inflammatory and immune mediators.
  • a number of the observed side effects may be due to the cross-reactivity of the currently available glucocorticoids with other steroid receptors, particularly the mineralocorticoid and progesterone receptors.
  • ligands for the glucocorticoid receptor that are highly selective and, upon binding, can dissociate the transactivation and transrepression pathways, providing therapeutic agents with a reduced side effect profile.
  • Assay systems to determine effects on transactivation and transrepression have been described (e.g., C.M. Bamberger and H.M. Schulte, Eur. J. Clin. Invest., 2000, 30 (suppl. 3), pp. 6-9).
  • Selectivity for the glucocorticoid receptor may be determined by comparing the binding affinity for this receptor with that of other steroid family receptors including those mentioned above.
  • Glucocorticoids also stimulate the production of glucose in the liver by a process called gluconeogenesis and it is believed that this process is mediated by transactivation events. Increased glucose production can exacerbate type II diabetes, therefore a compound that selectivity inhibited glucocorticoid mediated glucose production may have therapeutic utility in this indication (J.E. Freidman et al., J. Biol. Chem., 1997, 272, pp. 31475-31481).
  • PCT International Publication No. WO 99/33786 discloses triphenylpropanamide compounds with potential use in treating inflammatory diseases.
  • PCT International Publication No. WO 00/66522 describes non-steroidal compounds as selective modulators of the glucocorticoid receptor potentially useful in treating metabolic and inflammatory diseases.
  • PCT International Publication No. WO 99/41256 describes tetracyclic modulators of the glucocorticoid receptor potentially useful in treating immune, autoimmune, and inflammatory diseases.
  • U.S. Patent No. 5,688,810 describes various non-steroidal compounds as modulators of glucocorticoid and other steroid receptors.
  • PCT International Publication No. WO 99/63976 describes a non-steroidal, liver-selective glucocorticoid antagonist potentially useful in the treatment of diabetes.
  • PCT International Publication No. WO 00/32584 discloses non-steroidal compounds having anti-inflammatory activity with dissociation between anti-inflammatory and metabolic effects.
  • PCT International Publication No. WO 98/54159 describes non-steroidal cyclically substituted acylanilides with mixed gestagen and androgen activity.
  • U.S. Patent No. 4,880,839 describes acylanilides having progestational activity and EP 253503 discloses acylanilides with antiandrogenic properties.
  • PCT International Publication No. WO 97/27852 describes amides that are inhibitors of farnesyl-protein transferase.
  • a compound that is found to interact with the glucocorticoid receptor in a binding assay could be an agonist or an antagonist.
  • the agonist properties of the compound could be evaluated in the transactivation or transrepression assays described above.
  • the compound may be found to have antagonist activity.
  • glucocorticoids stimulate glucose production in the liver.
  • a ligand for the glucocorticoid receptor that is found to be an antagonist may be useful, inter alia, for treating or preventing diabetes.
  • Another aspect of the invention includes compounds of Formula (I), wherein:
  • R 6 is an aryl group optionally substituted with one to three substituent groups and wherein each substituent group of R 6 is independently: C 1 -C 5 alkyl, C 2 -C 5 alkenyl, C 2 -C 5 alkynyl, C 3 -C 8 cycloalkyl, C 1 -C 5 alkoxy, C 1 -C 5 alkanoyl, C 1 -C 5 alkoxycarbonyl, C 1 -C 5 alkanoyloxy, C 1 -C 5 alkylaminocarbonyloxy, C 1 -C 5 dialkylaminocarbonyloxy, C 1 -C 5 alkylaminocarbonyl, C 1 -C 5 dialkylaminocarbonyl, C 1 -C 5 alkanoylamino, C 1 -C 5 alkoxycarbonylamino, C 1 -C 5 alkylsulfonylamino,
  • Preferred compounds include the following:
  • More preferred compounds include:
  • the compounds according to the invention are formulated into pharmaceutical compositions comprising an effective amount, preferably a pharmaceutically effective amount, of a compound according to the invention or a tautomer, prodrug, solvate, or salt thereof, and a pharmaceutically acceptable excipient or carrier.
  • the invention describes a method of modulating the glucocorticoid receptor function in a patient, the method comprising administering to the patient an effective amount of a compound according to the invention or a tautomer, prodrug, solvate, or salt thereof.
  • the invention further describes a method of treating a disease-state or condition mediated by the glucocorticoid receptor function in a patient in need of such treatment, the method comprising administering to the patient an effective amount of a pharmaceutically acceptable compound according to the invention or a tautomer, prodrug, solvate, or salt thereof.
  • the invention describes a method of treating a disease-state or condition selected from: type II diabetes, obesity, cardiovascular diseases, hypertension, arteriosclerosis, neurological diseases, adrenal and pituitary tumors, and glaucoma, in a patient in need of such treatment, the method comprising administering to the patient an effective amount of a pharmaceutically acceptable compound according to the invention or a tautomer, prodrug, solvate, or salt thereof.
  • the invention discloses a method of treating a disease characterized by inflammatory, allergic, or proliferative processes, in a patient in need of such treatment, the method comprising administering to the patient an effective amount of a pharmaceutically acceptable compound according to the invention or a tautomer, prodrug, solvate, or salt thereof.
  • the disease characterized by inflammatory, allergic, or proliferative processes is selected from: (i) lung diseases; (ii) rheumatic diseases or autoimmune diseases or joint diseases; (iii) allergic diseases; (iv) vasculitis diseases; (v) dermatological diseases; (vi) renal diseases; (vii) hepatic diseases; (viii) gastrointestinal diseases; (ix) proctological diseases; (x) eye diseases; (xi) diseases of the ear, nose, and throat (ENT) area; (xii) neurological diseases; (xiii) blood diseases; (xiv) tumor diseases; (xv) endocrine diseases; (xvi) organ and tissue transplantations and graft-versus-host diseases; (xvii) severe states of shock; (xviii) substitution therapy; and (xix) pain of inflammatory genesis.
  • the disease characterized by inflammatory, allergic, or proliferative processes is selected from: type I diabetes, osteoarthritis, Guillain-Barre syndrome, restenosis following percutaneous transluminal coronary angioplasty, Alzheimer disease, acute and chronic pain, atherosclerosis, reperfusion injury, bone resorption diseases, congestive heart failure; myocardial infarction, thermal injury, multiple organ injury secondary to trauma, acute purulent meningitis, necrotizing enterocolitis, and syndromes associated with hemodialysis, leukopheresis, and granulocyte transfusion.
  • the invention further discloses a method of assaying the glucocorticoid receptor function in a sample, comprising: (a) contacting the sample with a selected amount of a compound according to the invention or a tautomer, prodrug, solvate, or salt thereof; and (b) detecting the amount of the compound according to the invention or a tautomer, prodrug, solvate, or salt thereof bound to glucocorticoid receptors in the sample.
  • the compound according to the invention or a tautomer, prodrug, solvate, or salt thereof is labeled with a detectable marker selected from: a radiolabel, fluorescent tag, a chemiluminescent tag, a chromophore, and a spin label.
  • a detectable marker selected from: a radiolabel, fluorescent tag, a chemiluminescent tag, a chromophore, and a spin label.
  • the invention discloses a method of imaging the glucocorticoid receptor distribution in a sample or patient, the method comprising: (a) contacting the sample or administering to a patient a compound according to the invention or a tautomer, prodrug, solvate, or salt thereof having a detectable marker, (b) detecting the spatial distribution and amount of the compound according to the invention or a tautomer, prodrug, solvate, or salt thereof having a detectable marker bound to glucocorticoid receptors in the sample or patient using an imaging means to obtain an image; and (c) displaying an image of the spatial distribution and amount of the compound according to the invention or a tautomer, prodrug, solvate, or salt thereof having a detectable marker bound to glucocorticoid receptors in the sample.
  • the imaging means is selected from: radioscintigraphy, nuclear magnetic resonance imaging (MRI), computed tomography (CT scan), or positron emission to
  • the invention also describes a kit for the in vitro diagnostic determination of the glucocorticoid receptor function in a sample, comprising: (a) a diagnostically effective amount of a compound according to the invention or a tautomer, prodrug, solvate, or salt thereof; and (b) instructions for use of the diagnostic kit.
  • the invention further provides a method of making a compound of Formula (I) where R 1 , R 2 , R 3 , R 5 , and R 6 are as defined above and R 4 is CH 2 , the method comprising:
  • C 1 -C 10 alkyl means an alkyl, group or radical having 1 to 10 carbon atoms.
  • the term "lower” applied to any carbon-containing group means a group containing from 1 to 8 carbon atoms, as appropriate to the group (i.e., a cyclic group must have at least 3 atoms to constitute a ring).
  • alkylaryl means a monovalent radical of the formula Alk-Ar-
  • arylalkyl means a monovalent radical of the formula Ar-Alk- (where Alk is an alkyl group and Ar is an aryl group).
  • alk is an alkyl group
  • Ar is an aryl group.
  • a term designating a monovalent radical where a divalent radical is appropriate shall be construed to designate the respective divalent radical and vice versa.
  • conventional definitions of terms control and conventional stable atom valences are presumed and achieved in all formulas and groups.
  • alkyl or "alkyl group” mean a branched or straight-chain saturated aliphatic hydrocarbon monovalent radical. This term is exemplified by groups such as methyl, ethyl, n -propyl, 1-methylethyl (isopropyl), n -butyl, n -pentyl, 1,1-dimethylethyl ( tert- butyl), and the like. It may be abbreviated "Alk”.
  • alkenyl or "alkenyl group” mean a branched or straight-chain aliphatic hydrocarbon monovalent radical containing at least one carbon-carbon double bond. This term is exemplified by groups such as ethenyl, propenyl, n -butenyl, isobutenyl, 3-methylbut-2-enyl, n -pentenyl, heptenyl, octenyl, decenyl, and the like.
  • alkynyl or "alkynyl group” mean a branched or straight-chain aliphatic hydrocarbon monovalent radical containing at least one carbon-carbon triple bond. This term is exemplified by groups such as ethynyl, propynyl, n -butynyl, 2-butynyl, 3-methylbutynyl, n -pentynyl, heptynyl, octynyl, decynyl, and the like.
  • alkylene or "alkylene group” mean a branched or straight-chain saturated aliphatic hydrocarbon divalent radical having the specified number of carbon atoms. This term is exemplified by groups such as methylene, ethylene, propylene, n -butylene, and the like, and may alternatively and equivalently be denoted herein as -(alkyl)-.
  • alkenylene or "alkenylene group” mean a branched or straight-chain aliphatic hydrocarbon divalent radical having the specified number of carbon atoms and at least one carbon-carbon double bond. This term is exemplified by groups such as ethenylene, propenylene, n-butenylene, and the like, and may alternatively and equivalently be denoted herein as -(alkylenyl)-.
  • alkynylene or "alkynylene group” mean a branched or straight-chain aliphatic hydrocarbon divalent radical containing at least one carbon-carbon triple bond. This term is exemplified by groups such as ethynylene, propynylene, n-butynylene, 2-butynylene, 3-methylbutynylene, n -pentynylene, heptynylene, octynylene, decynylene, and the like, and may alternatively and equivalently be denoted herein as -(alkynyl)-.
  • alkoxy or "alkoxy group” mean a monovalent radical of the formula AlkO-, where Alk is an alkyl group. This term is exemplified by groups such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butoxy, tert -butoxy, pentoxy, and the like.
  • aryloxy means a monovalent radical of the formula ArO-, where Ar is aryl. This term is exemplified by groups such as phenoxy, naphthoxy, and the like.
  • alkylcarbonyl means a monovalent radical of the formula AlkC(O)-, where Alk is alkyl or hydrogen.
  • arylcarbonyl means a monovalent radical of the formula ArC(O)-, where Ar is aryl.
  • acyl or "acyl group” mean a monovalent radical of the formula RC(O)-, where R is a substituent selected from hydrogen or an organic substituent.
  • substituents include alkyl, aryl, arylalkyl, cycloalkyl, heterocyclyl, heteroaryl, heteroarylalkyl, and the like. As such, the terms comprise alkylcarbonyl groups and arylcarbonyl groups.
  • acylamino or "acylamino group” mean a monovalent radical of the formula RC(O)N(R)-, where each R is a substituent selected from hydrogen or a substituent group.
  • alkoxycarbonyl or "alkoxycarbonyl group” mean a monovalent radical of the formula AlkO-C(O)-, where Alk is alkyl.
  • alkoxycarbonyl groups include methoxycarbonyl, ethoxycarbonyl, tert -butyloxycarbonyl, and the like.
  • alkylcarbonyloxy or “alkylcarbonyloxy group” or “alkanoyloxy” or “alkanoyloxy group” mean a monovalent radical of the formula AlkC(O)O-, where Alk is alkyl.
  • arylcarbonyloxy or "arylcarbonyloxy group” or “aroyloxy” or “aroyloxy group” mean a monovalent radical of the formula ArC(O)O-, where Ar is aryl.
  • alkylaminocarbonyloxy or “alkylaminocarbonyloxy group” mean a monovalent radical of the formula R 2 NC(O)O-, where each R is independently hydrogen or lower alkyl.
  • alkoxycarbonylamino or "alkoxycarbonylamino group” mean a monovalent radical of the formula ROC(O)NH-, where R is lower alkyl.
  • alkylcarbonylamino or “alkylcarbonylamino group” or “alkanoylamino” or “alkanoylamino groups” mean a monovalent radical of the formula AlkC(O)NH-, where Alk is alkyl.
  • alkylcarbonylamino groups include acetamido (CH 3 C(O)NH-).
  • alkylaminocarbonyloxy or “alkylaminocarbonyloxy group” mean a monovalent radical of the formula AlkNHC(O)O-, where Alk is alkyl.
  • amino or “amino group” mean an -NH 2 group.
  • alkylamino or "alkylamino group” mean a monovalent radical of the formula (Alk)NH-, where Alk is alkyl.
  • alkylamino groups include methylamino, ethylamino, propylamino, butylamino, tert- butylamino, and the like.
  • dialkylamino or "dialkylamino group” mean a monovalent radical of the formula (Alk)(Alk)N-, where each Alk is independently alkyl.
  • exemplary dialkylamino groups include dimethylamino, methylethylamino, diethylamino, dipropylamino, ethylpropylamino, and the like.
  • substituted amino or “substituted amino group” mean a monovalent radical of the formula -NR 2 , where each R is independently a substituent selected from hydrogen or the specified substituents (but where both Rs cannot be hydrogen).
  • substituents include alkyl, alkanoyl, aryl, arylalkyl, cycloalkyl, heterocyclyl, heteroaryl, heteroarylalkyl, and the like.
  • alkoxycarbonylamino or "alkoxycarbonylamino group” mean a monovalent radical of the formula AlkOC(O)NH-, where Alk is alkyl.
  • ureido or "ureido group” mean a monovalent radical of the formula R 2 NC(O)NH-, where each R is independently hydrogen or alkyl.
  • halo means one or more hydrogen atoms of the group are replaced by halogen groups.
  • haloalkyl or "haloalkyl group” mean a branched or straight-chain saturated aliphatic hydrocarbon monovalent radical, wherein one or more hydrogen atoms thereof are each independently replaced with halogen atoms. This term is exemplified by groups such as chloromethyl, 1,2-dibromoethyl, 1,1,1-trifluoropropyl, 2-iodobutyl, 1-chloro-2-bromo-3-fluoropentyl, and the like.
  • alkylthio or "alkylthio group” mean a monovalent radical of the formula AlkS-, where Alk is alkyl.
  • exemplary groups include methylthio, ethylthio, n -propylthio, isopropylthio, n -butylthio, and the like.
  • sulfonyl or "sulfonyl group” mean a divalent radical of the formula -SO 2 -.
  • sulfonylamino or "sulfonylamino group” mean a divalent radical of the formula -SO 2 NR-, where R is a hydrogen or a substituent group.
  • aminonosulfonyl or “aminosulfonyl group” mean a monovalent radical of the formula NR 2 SO 2 -, where R is each independently a hydrogen or a substituent group.
  • carbocycle or “carbocyclic group” mean a stable aliphatic 3- to 15-membered monocyclic or polycyclic monovalent or divalent radical consisting solely of carbon and hydrogen atoms which may comprise one or more fused or bridged ring(s), preferably a 5-to 7-membered monocyclic or 7- to 10-membered bicyclic ring. Unless otherwise specified, the carbocycle may be attached at any carbon atom which results in a stable structure and, if substituted, may be substituted at any suitable carbon atom which results in a stable structure.
  • the term comprises cycloalkyl (including spiro cycloalkyl), cycloalkylene, cycloalkenyl, cycloalkenylene, cycloalkynyl, and cycloalkynylene, and the like.
  • cycloalkyl or "cycloalkyl group” mean a stable aliphatic saturated 3- to 15-membered monocyclic or polycyclic monovalent radical consisting solely of carbon and hydrogen atoms which may comprise one or more fused or bridged ring(s), preferably a 5-to 7-membered monocyclic or 7- to 10-membered bicyclic ring. Unless otherwise specified, the cycloalkyl ring may be attached at any carbon atom which results in a stable structure and, if substituted, may be substituted at any suitable carbon atom which results in a stable structure.
  • Exemplary cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, norbomanyl, adamantyl, tetrahydronaphthyl (tetralin), 1-decalinyl, bicyclo[2.2.2]octanyl, 1-methylcyclopropyl, 2-methylcyclopentyl, 2-methylcyclooctyl, and the like.
  • cycloalkenyl or “cycloalkenyl group” mean a stable aliphatic 5- to 15-membered monocyclic or polycyclic monovalent radical having at least one carbon-carbon double bond and consisting solely of carbon and hydrogen atoms which may comprise one or more fused or bridged ring(s), preferably a 5- to 7-membered monocyclic or 7- to 10-membered bicyclic ring.
  • the cycloalkenyl ring may be attached at any carbon atom which results in a stable structure and, if substituted, may be substituted at any suitable carbon atom which results in a stable structure.
  • Exemplary cycloalkenyl groups include cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclononenyl, cyclodecenyl, norbomenyl, 2-methylcyclopentenyl, 2-methylcyclooctenyl, and the like.
  • cycloalkynyl or “cycloalkynyl group” mean a stable aliphatic 8- to 15-membered monocyclic or polycyclic monovalent radical having at least one carbon-carbon triple bond and consisting solely of carbon and hydrogen atoms which may comprise one or more fused or bridged ring(s), preferably a 8- to 10-membered monocyclic or 12- to 15-membered bicyclic ring.
  • the cycloalkynyl ring may be attached at any carbon atom which results in a stable structure and, if substituted, may be substituted at any suitable carbon atom which results in a stable structure.
  • Exemplary cycloalkynyl groups include, cyclooctynyl, cyclononynyl, cyclodecynyl, 2-methylcyclooctynyl, and the like.
  • cycloalkylene or "cycloalkylene group” mean a stable saturated aliphatic 3- to 15-membered monocyclic or polycyclic divalent radical consisting solely of carbon and hydrogen atoms which may comprise one or more fused or bridged ring(s), preferably a 5-to 7-membered monocyclic or 7- to 10-membered bicyclic ring. Unless otherwise specified, the cycloalkyl ring may be attached at any carbon atom which results in a stable structure and, if substituted, may be substituted at any suitable carbon atom which results in a stable structure.
  • Exemplary cycloalkylene groups include cyclopentylene, and the like.
  • cycloalkenylene or "cycloalkenylene group” mean a stable aliphatic 5- to 15-membered monocyclic or polycyclic divalent radical having at least one carbon-carbon double bond and consisting solely of carbon and hydrogen atoms which may comprise one or more fused or bridged ring(s), preferably a 5- to 7-membered monocyclic or 7- to 10-membered bicyclic ring.
  • the cycloalkenylene ring may be attached at any carbon atom which results in a stable structure and, if substituted, may be substituted at any suitable carbon atom which results in a stable structure.
  • Exemplary cycloalkenylene groups include cyclopentenylene, cyclohexenylene, cycloheptenylene, cyclooctenylene, cyclononenylene, cyclodecenylene, norbomenylene, 2-methylcyclopentenylene, 2-methylcyclooctenylene, and the like.
  • cycloalkynylene or "cycloalkynylene group” mean a stable aliphatic 8- to 15-membered monocyclic or polycyclic divalent radical having at least one carbon-carbon triple bond and consisting solely of carbon and hydrogen atoms which may comprise one or more fused or bridged ring(s), preferably a 8- to 10-membered monocyclic or 12- to 15-membered bicyclic ring. Unless otherwise specified, the cycloalkynylene ring may be attached at any carbon atom which results in a stable structure and, if substituted, may be substituted at any suitable carbon atom which results in a stable structure.
  • Exemplary cycloalkynylene groups include cyclooctynylene, cyclononynylene, cyclodecynylene, 2-methylcyclooctynylene, and the like.
  • aryl or “aryl group” mean an aromatic carbocyclic monovalent or divalent radical of from 6 to 14 carbon atoms having a single ring (e.g., phenyl or phenylene) or multiple condensed rings (e.g., naphthyl or anthranyl). Unless otherwise specified, the aryl ring may be attached at any suitable carbon atom which results in a stable structure and, if substituted, may be substituted at any suitable carbon atom which results in a stable structure.
  • Exemplary aryl groups include phenyl, naphthyl, anthryl, phenanthryl, indanyl, indenyl, biphenyl, and the like. It may be abbreviated "Ar".
  • heteroaryl or “heteroaryl group” mean a stable aromatic 5- to 14-membered, monocyclic or polycyclic monovalent or divalent radical which may comprise one or more fused or bridged ring(s), preferably a 5- to 7-membered monocyclic or 7- to 10-membered bicyclic radical, having from one to four heteroatoms in the ring(s) independently selected from nitrogen, oxygen, and sulfur, wherein any sulfur heteroatoms may optionally be oxidized and any nitrogen heteroatom may optionally be oxidized or be quaternized.
  • the heteroaryl ring may be attached at any suitable heteroatom or carbon atom which results in a stable structure and, if substituted, may be substituted at any suitable heteroatom or carbon atom which results in a stable structure.
  • exemplary and preferred heteroaryls include furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, tetrazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolizinyl, azaindolizinyl, indolyl, azaindolyl, diazaindolyl, dihydroindolyl, dihydroazaindoyl, isoindolyl, azaiso
  • heterocycle means a stable non-aromatic 5- to 14-membered monocyclic or polycyclic, monovalent or divalent, ring which may comprise one or more fused or bridged ring(s), preferably a 5- to 7-membered monocyclic or 7- to 10-membered bicyclic ring, having from one to three heteroatoms in the ring(s) independently selected from nitrogen, oxygen, and sulfur, wherein any sulfur heteroatoms may optionally be oxidized and any nitrogen heteroatom may optionally be oxidized or be quaternized.
  • the heterocyclyl ring may be attached at any suitable heteroatom or carbon atom which results in a stable structure and, if substituted, may be substituted at any suitable heteroatom or carbon atom which results in a stable structure.
  • exemplary and preferred heterocycles include pyrrolinyl, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrofuranyl, hexahydropyrimidinyl, hexahydropyridazinyl, and the like.
  • compounds of the invention are meant to embrace compounds of Formula (I) as herein described, including the tautomers, the prodrugs, the salts, particularly the pharmaceutically acceptable salts, and the solvates and hydrates thereof, where the context so permits.
  • the compounds of the invention and the formulas designating the compounds of the invention are understood to only include the stable compounds thereof and exclude unstable compounds, even if an unstable compound might be considered to be literally embraced by the compound formula.
  • reference to intermediates, whether or not they themselves are claimed is meant to embrace their salts and solvates, where the context so permits. For the sake of clarity, particular instances when the context so permits are sometimes indicated in the text, but these instances are purely illustrative and it is not intended to exclude other instances when the context so permits.
  • stable compound or “stable structure” mean a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic or diagnostic agent.
  • a compound which would have a "dangling valency" or is a carbanion is not a compound contemplated by the invention.
  • substituted means that any one or more hydrogens on an atom of a group or moiety, whether specifically designated or not, is replaced with a selection from the indicated group of substituents, provided that the atom's normal valency is not exceeded and that the substitution results in a stable compound. If a bond to a substituent is shown to cross the bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring. When a substituent is listed without indicating the atom via which such substituent is bonded to the rest of the compound, then such substituent may be bonded via any atom in such substituent.
  • such piperazinyl, piperidinyl, or tetrazolyl group may be bonded to the rest of the compound of the invention via any atom in such piperazinyl, piperidinyl, or tetrazolyl group.
  • any substituent or group occurs more than one time in any constituent or compound, its definition on each occurrence is independent of its definition at every other occurrence.
  • the term “about” or “approximately” means within 20%, preferably within 10%, and more preferably within 5% of a given value or range.
  • prodrug or “prodrug derivative” mean a covalently-bonded derivative or carrier of the parent compound or active drug substance which undergoes at least some biotransformation prior to exhibiting its pharmacological effect(s).
  • prodrugs have metabolically cleavable groups and are rapidly transformed in vivo to yield the parent compound, for example, by hydrolysis in blood, and generally include esters and amide analogs of the parent compounds.
  • the prodrug is formulated with the objectives of improved chemical stability, improved patient acceptance and compliance, improved bioavailability, prolonged duration of action, improved organ selectivity, improved formulation (e.g., increased hydrosolubility), and/or decreased side effects (e.g., toxicity).
  • prodrugs themselves have weak or no biological activity and are stable under ordinary conditions.
  • Prodrugs can be readily prepared from the parent compounds using methods known in the art, such as those described in A Textbook of Drug Design and Development, Krogsgaard-Larsen and H. Bundgaard (eds.), Gordon & Breach, 1991, particularly Chapter 5: "Design and Applications of Prodrugs”; Design of Produgs, H. Bundgaard (ed.), Elsevier, 1985; Prodrugs: Topical and Ocular Drug Delivery, K.B. Sloan (ed.), Marcel Dekker, 1998; Methods in Enzymology, K. Widder et al . (eds.), Vol.
  • pharmaceutically acceptable prodrug means a prodrug of a compound of the invention which is, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as weD as the zwitterionic forms, where possible.
  • salt means an ionic form of the parent compound or the product of the reaction between the parent compound with a suitable acid or base to make the acid salt or base salt of the parent compound.
  • Salts of the compounds of the present invention can be synthesized from the parent compounds which contain a basic or acidic moiety by conventional chemical methods. Generally, the salts are prepared by reacting the free base or acid parent compound with stoichiometric amounts or with an excess of the desired salt-forming inorganic or organic acid or base in a suitable solvent or various combinations of solvents.
  • pharmaceutically acceptable salt means a salt of a compound of the invention which is, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, generally water or oil-soluble or dispersible, and effective for their intended use.
  • pharmaceutically-acceptable acid addition salts and pharmaceutically-acceptable base addition salts.
  • the use of the salt form amounts to use of the base form. Lists of suitable salts are found in, e.g., S.M. Birge et al ., J. Pharm. Sci., 1977, 66 , pp. 1-19.
  • pharmaceutically-acceptable acid addition salt means those salts which retain the biological effectiveness and properties of the free bases and which are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, nitric acid, phosphoric acid, and the like, and organic acids such as acetic acid, trichloroacetic acid, trifluoroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 2-acetoxybenzoic acid, butyric acid, camphoric acid, camphorsulfonic acid, cinnamic acid, citric acid, digluconic acid, ethanesulfonic acid, glutamic acid, glycolic acid, glycerophosphoric acid, hemisulfic acid, heptanoic acid, hexanoic acid, formic acid, fum
  • pharmaceutically-acceptable base addition salt means those salts which retain the biological effectiveness and properties of the free acids and which are not biologically or otherwise undesirable, formed with inorganic bases such as ammonia or hydroxide, carbonate, or bicarbonate of ammonium or a metal cation such as sodium, potassium, lithium, calcium, magnesium, iron, zinc, copper, manganese, aluminium, and the like. Particularly preferred are the ammonium, potassium, sodium, calcium, and magnesium salts.
  • Salts derived from pharmaceutically-acceptable organic nontoxic bases include salts of primary, secondary, and tertiary amines, quaternary amine compounds, substituted amines including naturally occurring substituted amines, cyclic amines and basic ionexchange resins, such as methylamine, dimethylamine, trimethylamine, ethylamine, diethylamine, triethylamine, isopropylamine, tripropylamine, tributylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N- ethylpiperidine, tetramethylammonium compounds, tetraethylammonium
  • solvate means a physical association of a compound with one or more solvent molecules or a complex of variable stoichiometry formed by a solute (for example, a compound of Formula (I)) and a solvent, for example, water, ethanol, or acetic acid. This physical association may involve varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances, the solvate will be capable of isolation, for example, when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. In general, the solvents selected do not interfere with the biological activity of the solute. Solvates encompasses both solution-phase and isolatable solvates. Representative solvates include hydrates, ethanolates, methanolates, and the like.
  • hydrate means a solvate wherein the solvent molecule(s) is/are H 2 O.
  • the compounds of the present invention as discussed below include the free base or acid thereof, their salts, solvates, and prodrugs and may include oxidized sulfur atoms or quaternized nitrogen atoms in their structure, although not explicitly stated or shown, particularly the pharmaceutically acceptable forms thereof. Such forms, particularly the pharmaceutically acceptable forms, are intended to be embraced by the appended claims.
  • isomer means compounds having the s ame number and kind of a toms, and hence the same molecular weight, but differing with respect to the arrangement or configuration of the atoms in space.
  • the term includes stereoisomers and geometric isomers.
  • stereoisomer means a stable isomer that has at least one chiral atom or restricted rotation giving rise to perpendicular dissymmetric planes (e.g., certain biphenyls, allenes, and spiro compounds) and can rotate plane-polarized light. Because asymmetric centers and other chemical structure exist in the compounds of the invention which may give rise to optical isomerism, the invention contemplates stereoisomers and mixtures thereof.
  • the compounds of the invention and their salts include asymmetric carbon atoms and may therefore exist as single stereoisomers, racemates, and as mixtures of enantiomers and diastereomers. Typically, such compounds will be prepared as a racemic mixture.
  • Such compounds can be prepared or isolated as pure optical isomers, i.e., as individual enantiomers or diastereomers, or as stereoisomer-enriched mixtures.
  • Individual stereoisomers of compounds are prepared by synthesis from optically active starting materials containing the desired chiral centers or by preparation of mixtures of enantiomeric products followed by separation, such as conversion to a mixture of diastereomers followed by separation or recrystallization, chromatographic techniques, use of chiral resolving agents, or direct separation of the enantiomers on chiral chromatographic columns.
  • Starting compounds of particular stereochemistry are either commercially available or are made by the methods described below and resolved by techniques well-known in the art.
  • antiomers means a pair of optical isomers that are non-superimposable mirror images of each other.
  • diastereoisomers or “diastereomers” mean stereoisomers which are not mirror images of each other.
  • racemic mixture or “racemate” mean a mixture containing equal parts of individual enantiomers.
  • non-racemic mixture means a mixture containing unequal parts of individual enantiomers.
  • Some of the compounds of the invention can exist in more than one tautomeric form. As mentioned above, the compounds of the invention include all such tautomers.
  • patient includes both human and non-human mammals.
  • effective amount means an amount of a compound according to the invention which, in the context of which it is administered or used, is sufficient to achieve the desired effect or result.
  • effective amount may include or be synonymous with a pharmaceutically effective amount or a diagnostically effective amount.
  • pharmaceutically effective amount or “therapeutically effective amount” means an amount of a compound according to the invention which, when administered to a patient in need thereof, is sufficient to effect treatment for disease-states, conditions, or disorders for which the compounds have utility. Such an amount would be sufficient to elicit the biological or medical response of a tissue, system, or patient that is sought by a researcher or clinician.
  • the amount of a compound of according to the invention which constitutes a therapeutically effective amount will vary depending on such factors as the compound and its biological activity, the composition used for administration, the time of administration, the route of administration, the rate of excretion of the compound, the duration of treatment, the type of disease-state or disorder being treated and its severity, drugs used in combination with or coincidentally with the compounds of the invention, and the age, body weight, general health, sex, and diet of the patient.
  • a therapeutically effective amount c an be determined routinely by one of ordinary skill in the art having regard to their own knowledge, the prior art, and this disclosure.
  • diagnostically effective amount means an amount of a compound according to the invention which, when used in a diagnostic method, apparatus, or assay, is sufficient to achieve the desired diagnostic effect or the desired biological activity necessary for the diagnostic method, apparatus, or assay. Such an amount would be sufficient to elicit the biological or medical response in a diagnostic method, apparatus, or assay, which may include a biological or medical response in a patient or in a in vitro or in vivo tissue or system, that is sought by a researcher or clinician.
  • the amount of a compound according to the invention which constitutes a diagnostically effective amount will vary depending on such factors as the compound and its biological activity, the diagnostic method, apparatus, or assay used, the composition used for administration, the time of administration, the route of administration, the rate of excretion of the compound, the duration of administration, drugs and other compounds used in combination with or coincidentally with the compounds of the invention, and, if a patient is the subject of the diagnostic administration, the age, body weight, general health, sex, and diet of the patient.
  • a diagnostically effective amount can be determined routinely by one of ordinary skill in the art having regard to their own knowledge, the prior art, and this disclosure.
  • modulate means the ability of a compound to alter the function of the glucocorticoid receptor by, for example, binding to and stimulating or inhibiting the glucocorticoid receptor functional responses.
  • modulator in the context of describing compounds according to the invention means a compound that modulates the glucocorticoid receptor function.
  • modulators include, but are_not limited to, agonists, partial agonists, antagonists, and partial antagonists.
  • agonist in the context of describing compounds according to the invention means a compound that, when bound to the glucocorticoid receptor, enhances or increases the glucocorticoid receptor function.
  • agonists include partial agonists and full agonists.
  • full agonist in the context of describing compounds according to the invention means a compound that evokes the maximal stimulatory response from the glucocorticoid receptor, even when there are spare (unoccupied) glucocorticoid receptors present.
  • partial agonist in the context of describing compounds according to the invention means a compound that is unable to evoke the maximal stimulatory response from the glucocorticoid receptor, even at concentrations sufficient to saturate the glucocorticoid receptors present.
  • antagonist in the context of describing compounds according to the invention means a compound that directly or indirectly inhibits or suppresses the glucocorticoid receptor function.
  • antagonists include partial antagonists and full antagonists.
  • full antagonist in the context of describing compounds according to the invention means a compound that evokes the maximal inhibitory response from the glucocorticoid receptor, even when there are spare (unoccupied) glucocorticoid receptors present.
  • partial antagonist in the context of describing compounds according to the invention means a compound that is unable to evoke the maximal inhibitory response from the glucocorticoid receptor, even at concentrations sufficient to saturate the glucocorticoid receptors present.
  • treating or “treatment” mean the treatment of a disease-state in a patient, and include:
  • the invention also provides processes for making compounds of Formula (I).
  • R 1 to R 6 in the formulas below shall have the meaning of R 1 to R 6 in the Formula (I) of the invention described hereinabove.
  • Intermediates used in the preparation of compounds of the invention are either commercially available or readily prepared by methods known to those skilled in the art.
  • reaction conditions and reaction times may vary depending on the particular reactants used. Unless otherwise specified, solvents, temperatures, pressures, and other reaction conditions may be readily selected by one of ordinary skill in the art. Specific procedures are provided in the Synthetic Examples section. Typically, reaction progress may be monitored by thin layer chromatography (TLC), if desired, and intermediates and products may be purified by chromatography on silica gel and/or by recrystallization.
  • TLC thin layer chromatography
  • an oxalate ester preferably diethyl oxalate
  • an alkylmagnesium halide such as an alkylmagnesium bromide
  • R 1 , R 2 , and R 3 R 1 , R 2 , and R 3
  • alkylmagnesium halides or Grignard reagents are well known in the art and are easily prepared by reacting the corresponding alkyl halide with magnesium metal in a suitable solvent, such as ether or THF, under anhydrous conditions.
  • the resulting ketoester (III) is hydrolyzed, for example by refluxing with an aqueous base such as potassium hydroxide with a suitable co-solvent such as methanol.
  • the resulting ketoacid (IV) may be coupled with an amine bearing R 6 under standard coupling conditions well-known in the art (see, for example, M. Bodanszky, The Practice of Peptide Synthesis (Springer-Verlag: 1984). For example, one may convert the carboxylic acid to an acid chloride with an activating agent such as thionyl chloride, in a suitable solvent such as dimethylacetamide, followed by reaction of the acid chloride with R 6 NH 2 .
  • an activating agent such as thionyl chloride
  • an aryl bromide (R 1 Br) is reacted with an organometallic reagent such as n -butyllithium in a suitable solvent such as THF, preferably at about -78°C.
  • organometallic reagent such as n -butyllithium
  • THF a suitable solvent
  • the resulting anion is reacted with a ketone bearing R 2 and R 3 to give an alcohol bearing R 1 , R 2 , and R 3 (VI).
  • This alcohol is reacted with a silyl enol ether derived from ethyl pyruvate, in the presence of a Lewis acid such as stannic chloride, in a suitable solvent such as methylene chloride at about -78°C to -50°C to provide the ketoester intermediate bearing R 1 , R 2 , and R 3 (III).
  • a Lewis acid such as stannic chloride
  • a suitable solvent such as methylene chloride
  • the aryl or heteroaryl bromide R 1 Br is treated with an organometallic reagent such as n -butyl lithium in a suitable solvent such as THF at about -78°C.
  • organometallic reagent such as n -butyl lithium
  • a suitable solvent such as THF
  • the resulting anion undergoes addition to a methyl vinyl ketone bearing R 2 and R 3 (VII), for example, by treating with cuprous iodide in dimethylsulfide followed by chlorotrimethyl silane and then the ketone.
  • the resulting methyl ketone (VIII) is brominated by treating with a suitable brominating agent such as benzyltrimethylammonium tribromide in a suitable solvent such as methylene chloride.
  • the resulting bromoketone (IX) is reacted with an amine bearing R 6 in a suitable solvent such as acetonitrile at a temperature of from about ambient to about the reflux temperature of the solvent, to provide the corresponding aminoketone (X).
  • a suitable organometallic reagent R 5 M where M is Li or MgX, and X is Cl, Br, or I, that is, an organolithium reagent or alkylmagnesium halide bearing R 5 , produces the desired compound of Formula (I) where R 4 is CH 2 .
  • 2-Phenyl-2,2-dimethylethylmagnesium bromide (10 mmol, 20 mL of 0.5 M solution in diethyl ether) was added to solution of diethyl oxalate (1.5 g, 10.5 mmol) in anhydrous THF (20 mL) cooled to -78°C and maintained under argon. After 1 hour, TLC in hexanes-EtOAc (7:1) indicated most of the diethyl oxalate had been consumed. The reaction mixture was quenched with a saturated solution of ammonium chloride and extracted with three 50 mL portions of EtOAc.
  • reaction mixture was diluted with methylene chloride (50 mL), washed with two 50 mL portions of water, dried over anhydrous sodium sulfate, and concentrated in vacuo to give 1-bromo-4-(5-fluoro-2-methoxyphenyl)-4-methylpentan-2-one as a light brown liquid (80%) which was used for the next reaction without further purification.
  • glucocorticoid receptor GR
  • TAMRA tetramethyl rhodamine
  • the wavelengths for maximum excitation and emission of the fluorescent probe should first be measured.
  • An example of such a probe is rhodamine (TAMRA)-labeled dexamethasone.
  • the affinity of the probe for the steroid receptor was then determined in a titration experiment.
  • the fluorescence polarization value of the probe in assay buffer was measured on an SLM-8100 fluorometer using the excitation and emission maximum values described above. Aliquots of expression vector lysate were added and fluorescence polarization was measured after each addition until no further change in polarization value was observed. Non-linear least squares regression analysis was used to calculate the dissociation constant of the probe from the polarisation values obtained for lysate binding to the probe.
  • This assay uses fluorescence polarization (FP) to quantitate the ability of test compounds to compete with tetramethyl rhodamine (TAMRA)-labeled dexamethasone for binding to a human glucocorticoid receptor (GR) complex prepared from an insect expression system.
  • FP fluorescence polarization
  • the assay buffer was: 10 mM TES, 50 mM KC1, 20 mM Na 2 MoO 4 •2H 2 O, 1.5 mM EDTA, 0.04% w/v CHAPS, 10% v/v glycerol, 1 mM dithiothreitol, pH 7.4.
  • Test compounds were dissolved to 1 mM in neat DMSO and then further diluted to 10x assay concentration in assay buffer supplemented with 10% v/v DMSO. Test compounds were serially diluted at 10x assay concentrations in 10% DMSO-containing buffer in 96-well polypropylene plates.
  • Binding reaction mixtures were prepared in 96-well black Dynex microtiter plates by sequential addition of the following assay components to each well: 15 ⁇ L of 10x test compound solution, 85 ⁇ L of GR-containing baculovirus lysate diluted 1:170 in assay buffer, and 50 ⁇ L of 15 nM TAMRA-labeled dexamethasone. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing 0.7 ⁇ M to 2 ⁇ M dexamethasone.
  • the binding reactions were incubated for 1 hour at room temperature and then read for fluorescence polarization in the LJL Analyst set to 550 nm excitation and 580 nm emission, with the Rhodamine 561 dichroic mirror installed.
  • IC 50 values were determined by iterative non-linear curve fitting of the FP signal data to a 4-parameter logistic equation.
  • PR progesterone receptor
  • ER estrogen receptor
  • mineralocorticoid receptors to evaluate the compound's selectivity for GR.
  • PR insect cell lysate is diluted 1:7.1 and MR lysate diluted 1:9.4.
  • PR probe is TAMRA-labeled mifepristone, used at a final concentration of 5 nM in the assay, and the negative controls (blanks) were reactions containing mifepristone at 0.7 ⁇ M to 2 ⁇ M.
  • the ER protocol is similar to the above protocols, but uses PanVera kit receptor, fluorescein-labeled probe.
  • the assay components are made in the same volumes as above, to produce final assay concentrations for ER of 15 nM and ES2 probe of 1 nM.
  • the component order of addition is modified from the above assays: probe is added to the plate first, followed by receptor and test compound.
  • the plates are read in the LJL Analyst set to 485 nm excitation and 530 nm emission, with the Fluorescein 505 dichroic mirror installed.
  • Compounds found to bind to the glucocorticoid receptor may be evaluated for dissociation of transactivation and transrepression by assays cited in the Background of the Invention (C.M. Bamberger and H.M. Schulte, Eur. J. Clin. Invest., 2000, 30 (suppl. 3) 6-9) or by the assays described below.
  • Dexamethasone a synthetic ligand to the glucocorticoid receptor (GR) induces expression of aromatase in human foreskin fibroblast cells.
  • the activity of aromatase is measured by the conversion of testosterone to estradiol in culture media.
  • Compounds that exhibit binding to GR are evaluated for their ability to induce aromatase activity in human foreskin fibroblasts.
  • Human foreskin fibroblast cells (ATCC Cat. No. CRL-2429, designation CCD112SK) are plated on 96 well plates at 50,000 cells per well 5 days before use, in Iscove's Modified Dulbecco's Media (GibcoBRL Life Technologies Cat No. 12440-053) supplemented with 10% charcoal filtered FBS (Clonetech Cat No. SH30068) and Gentamycin (GibcoBRL Life Technologies Cat. No. 15710-064). On the day of the experiment, the media in the wells is replaced with fresh media. Cells are treated with test compounds to final concentrations of 10 -5 M to 10 -8 M, and testosterone to a final concentration of 300 ng/mL.
  • Control wells include: (a) wells that receive testosterone only, and (b) wells that receive testosterone plus 2 ⁇ M of dexamethasone to provide maximum induction of aromatase. Plates are incubated at 37°C overnight (15 to 18 hours), and supernatants are harvested at the end of incubation. Estradiol in the supernatant is measured using ELISA kits for estradiol (made by ALPCO, obtained from American Laboratory Products Cat. No. 020-DR-2693) according to the manufacture's instruction. The amount of estradiol is inversely proportional to the ELISA signals in each well. The extent of aromatase induction by test compounds is expressed as a relative percentage to dexamethasone. EC 50 values of test compounds are derived by non-linear curve fitting.
  • Human foreskin fibroblast cells produce IL-6 in response to stimulation by pro-inflammatory cytokine IL-1.
  • This inflammatory response as measured by the production of IL-6, can be effectively inhibited by dexamethasone, a synthetic ligand to the glucocorticoid receptor (GR).
  • dexamethasone a synthetic ligand to the glucocorticoid receptor (GR).
  • GR glucocorticoid receptor
  • Human foreskin fibroblast cells (ATCC Cat. No. CRL-2429) are plated on 96 well plates at 5,000 cells per well the day before use, in Iscove's Modified Dulbecco's Media (GibcoBRL Life Technologies Cat. No. 12440-053) supplemented with 10% charcoal filtered FBS (Clonetech Cat. No. SH30068) and Gentamycin (GibcoBRL Life Technologies Cat. No. 15710-064). On the next day, media in the wells is replaced with fresh media. Cells are treated with IL-1 (rhIL-1 ⁇ , R&D Systems Cat. No.
  • test compounds 200-LA to a final concentration of 1 ng/mL, and with test compounds to final concentrations of 10 -5 M to 10 -8 M, in a total volume of 200 ⁇ L per well.
  • Samples are done in duplicates. Background control wells do not receive test compounds or IL-1. Positive control wells receive IL-1 only and represent maximum (or 100%) amount of IL-6 production. Plates are incubated at 37°C overnight (15 to 18 hours), and supernatants are harvested at the end of incubation. IL-6 levels in the supernatants are determined by the ELISA kits for IL-6 (MedSystems Diagnostics GmbH, Vienna, Austria, Cat. No. BMS213TEN) according to manufacture's instructions. The extent of inhibition of IL-6 by test compounds is expressed in percentage relative to positive controls. IC 50 values of test compounds are derived by non-linear curve fitting.
  • Evaluation of agonist or antagonist activity of compounds binding to the glucocorticoid receptor may be determined by any of the assays.
  • TAT Tyrosine Aminotransferase
  • TAT tyrosine aminotransferase
  • H4-II-E-C3 cells were incubated overnight in 96 well plates (20,000 cells/100 ⁇ L/well) in MEM medium containing 10% heat inactivated FBS and 1% nonessential amino acids. On the next day, cells were stimulated with the indicated concentrations of dexamethasone or test compound (dissolved in DMSO, final DMSO concentration 0.2%) for 18 hours. Control cells were treated with 0.2% DMSO. After 18 hours, the cells were lysed in a buffer containing 0.1% Triton X-100 and the TAT activity was measured in a photometric assay using tyrosine and alpha-ketoglutarate as substrates.
  • the hepatoma cells were pre-stimulated by addition of dexamethasone (concentration ranges from 3 x 10 -9 M to 3 x 10 -8 M) shortly before the test compound was applied to the cells.
  • dexamethasone concentration ranges from 3 x 10 -9 M to 3 x 10 -8 M
  • the steroidal non-selective GR/PR antagonist mifepristone was used as control.
  • HeLa cells were stably co-transfected with the pHHLuc-plasmid containing a fragment of the MMTV-LTR (-200 to +100 relative to the transcription start site) cloned in front of the luciferase gene (Norden, 1988) and the pcDNA3.1 plasmid (Invitrogen) constitutively expressing the resistance for the selective antibiotic GENETICIN®. Clones with best induction of the MMTV-promoter were selected and used for further experiments.
  • the MMTV-promoter was pre-stimulated by adding dexamethasone (3 x 10 -9 M to 3 x 10 -8 M) shortly before the test compound was applied to the cells.
  • dexamethasone 3 x 10 -9 M to 3 x 10 -8 M
  • the steroidal non-selective GR/PR antagonist mifepristone was used as control.
  • U-937 cells were incubated for 2 to 4 days in RPMI1640 medium containing 10% CCS (charcoal treated calf serum). The cells were transferred to 96 well plates (40,000 cells/100 ⁇ L/well) and stimulated with 1 ⁇ g/mL LPS (dissolved in PBS) in the presence or absence of dexamethasone or test compound (dissolved in DMSO, final concentration 0.2%). Control cells were treated with 0.2% DMSO. After 18 hours, the IL-8 concentration in the cell supernatant was measured by ELISA, using the "OptEIA human IL-8 set" (Pharmingen, Cat No. 2654KI).
  • the LPS-induced IL-8 secretion was inhibited by adding dexamethasone (3 x 10 -9 M to 3 x 10 -8 M) shortly before the test compound was applied to the cells.
  • dexamethasone 3 x 10 -9 M to 3 x 10 -8 M
  • the steroidal non-selective GR/PR antagonist mifepristone was used as control.
  • HeLa cells were stably co-transfected with a plasmid containing a 1.3 kb fragment of the human ICAM-promoter (-1353 to -9 relative to the transcription start site, Ledebur and Parks, 1995) cloned in front of the luciferase gene and the pcDNA3.1 plasmid (Invitrogen) which constitutively expresses the resistance for the antibiotic GENETICIN®.
  • Clones with best induction of the ICAM-promoter were selected and used for further experiments. Cells were transferred to 96 well plates (15,000 cells/100 ⁇ L/well) in DMEM medium supplemented with 3% CCS.
  • the activation of the ICAM-promoter was induced by addition of 10 ng/mL recombinant TNF-alpha (R&D System, Cat. No. 210-TA). Simultaneously the cells were treated with the test compound or dexamethasone (dissolved in DMSO, final concentration 0.2%). Control cells were treated with DMSO only. After 18 hours, the cells were lysed with cell lysis reagent (Promega, Cat. No. E1531), luciferase assay reagent (Promega, Cat. No. E1501) was added and glow luminescence was measured using a luminometer (BMG, Offenburg).
  • the TNF-alpha-induced activation of the ICAM-promoter was inhibited by adding dexamethasone (3 x 10 -9 M to 3 x 10 -8 M) shortly before the test compound was applied to the cells.
  • dexamethasone 3 x 10 -9 M to 3 x 10 -8 M
  • the steroidal non-selective GR/PR antagonist mifepristone was used as control.
  • the preferred potency range in the above assays is between 0.1 nM and 10 ⁇ M, the more preferred potency range is 0.1 nM to 1 ⁇ M, and the most preferred potency range is 0.1 nM to 100 nM.
  • Representative compounds of the invention have been tested and have shown activity as modulators of the glucocorticoid receptor function in one or more of the above assays.
  • the following compounds of the invention have demonstrated potent activity in the GR binding assay:
  • the invention also provides methods of modulating the glucocorticoid receptor function in a patient comprising administering to the patient a compound according to the invention. If the purpose of modulating the glucocorticoid receptor function in a patient is to treat a disease-state or condition, the administration preferably comprises a therapeutically or pharmaceutically effective amount of a pharmaceutically acceptable compound according to the invention.
  • the administration preferably comprises an effective amount of a compound according to the invention, that is, the amount necessary to obtain the desired effect or degree of modulation.
  • the compounds of the invention are useful in modulating the glucocorticoid receptor function. In doing so, these compounds have therapeutic use in treating disease-states and conditions mediated by the glucocorticoid receptor function or that would benefit from modulation of the glucocorticoid receptor function.
  • the compounds of the invention modulate the glucocorticoid receptor function, they have very useful anti-inflammatory and antiallergic, immune-suppressive, and antiproliferative activity and they can be used in patients as drugs, particularly in the form of pharmaceutical compositions as set forth below, for the treatment of disease-states and conditions.
  • the agonist compounds according to the invention can be used in patients as drugs for the treatment of the following disease-states or indications that are accompanied by inflammatory, allergic, and/or proliferative processes:
  • the compounds according to the invention can be used for the treatment of any other disease-states or conditions not mentioned above which have been treated, are treated, or will be treated with synthetic glucocorticoids (see, e.g., H.J. Hatz, Glucocorticoide: Immunologische Grundlagen, Pharmakologie und Therapierichtlinien [Glucocorticoids: Immunological Fundamentals, Pharmacology, and Therapeutic Guidelines], Stuttgart: Verlagsgesellschaft mbH, 1998. Most or all of the indications (i) through (xx) mentioned above are described in detail in H.J, Hatz, Glucocorticoide: Immunologische Grundlagen, Pharmakologie und Therapierichtlinien .
  • the compounds of the invention can also be used to treat disorders other than those listed above or mentioned or discussed herein, including in the Background of the Invention.
  • the antagonist compounds according to the invention can be used in patients as drugs for the treatment of the following disease-states or indications, without limitation: type II diabetes (non-insulin-dependent diabetes); obesity; cardiovascular diseases; hypertension; arteriosclerosis; neurological diseases, such as psychosis and depression; adrenal and pituitary tumors; glaucoma; and Cushing syndrome based on an ACTH-secreting tumor like pituitary adenoma.
  • type II diabetes non-insulin-dependent diabetes
  • obesity cardiovascular diseases
  • hypertension arteriosclerosis
  • neurological diseases such as psychosis and depression
  • adrenal and pituitary tumors glaucoma
  • Cushing syndrome based on an ACTH-secreting tumor like pituitary adenoma.
  • the compounds of the invention are useful for treating obesity and all disease-states and indications related to a deregulated fatty acids metabolism such as hypertension, atherosclerosis, and other cardiovascular diseases.
  • the antagonist compounds of the invention are useful in Heating all disease-states and conditions that involve increased carbohydrate, protein, and lipid metabolism and would include disease-states and conditions leading to catabolism like muscle frailty (as an example of protein metabolism).
  • the compounds of the invention may also be used in diagnostic applications and for commercial and other purposes as standards in competitive binding assays.
  • the compounds of the invention may be used in the from of the compounds themselves or they may be modified by attaching a radioisotope, luminescence, fluorescent label or the like in order to obtain a radioisotope, luminescence, or fluorescent probe, as would be known by one of skill in the art and as outlined in Handbook of Fluorescent Probes and Research Chemicals, 6th Edition, R.P. Haugland (ed.), Eugene: Molecular Probes, 1996; Fluorescence and Luminescence Probes for Biological Activity , W.T. Mason (ed.), San Diego: Academic Press, 1993; Receptor-Ligand Interaction, A Practical Approach, E.C. Hulme (ed.), Oxford: IRL Press, 1992.
  • the compounds of the invention are typically administered in the form of a pharmaceutical composition.
  • Such compositions can be prepared using procedures well known in the pharmaceutical art and comprise at least one compound of the invention.
  • the compounds of the invention may also be administered alone or in combination with adjuvants that enhance stability of the compounds of the invention, facilitate administration of pharmaceutical compositions containing them in certain embodiments, provide increased dissolution or dispersion, increased inhibitory activity, provide adjunct therapy, and the like.
  • the compounds according to the invention may be used on their own or in conjunction with other active substances according to the invention, optionally also in conjunction with other pharmacologically active substances.
  • the compounds of this invention are administered in a therapeutically or pharmaceutically effective amount, but may be administered in lower amounts for diagnostic or other purposes.
  • Administration of the compounds of the invention, in pure form or in an appropriate pharmaceutical composition can be carried out using any of the accepted modes of administration of pharmaceutical compositions.
  • administration can be, for example, orally, buccally (e.g., sublingually), nasally, parenterally, topically, transdermally, vaginally, or rectally, in the form of solid, semi-solid, lyophilized powder, or liquid dosage forms, such as, for example, tablets, suppositories, pills, soft elastic and hard gelatin capsules, powders, solutions, suspensions, or aerosols, or the like, preferably in unit dosage forms suitable for simple administration of precise dosages.
  • the pharmaceutical compositions will generally include a conventional pharmaceutical carrier or excipient and a compound of the invention as the/an active agent, and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, diluents, vehicles, or combinations thereof.
  • Such pharmaceutically acceptable excipients, carriers, or additives as well as methods of making pharmaceutical compositions for various modes or administration are well-known to those of skill in the art. The state of the art is evidenced, e.g., by Remington: The Science and Practice of Pharmacy , 20th Edition, A.
  • the forms of the compounds of the invention utilized in a particular pharmaceutical formulation will be selected (e.g., salts) that possess suitable physical characteristics (e.g., water solubility) that is required for the Simulation to be efficacious.
  • compositions suitable for buccal (sub-lingual) administration include lozenges comprising a compound of the present invention in a flavored base, usually sucrose, and acacia or tragacanth, and pastilles comprising the compound in an inert base such as gelatin and glycerin or sucrose and acacia.
  • compositions suitable for parenteral administration comprise sterile aqueous preparations of a compound of the present invention. These preparations are preferably administered intravenously, although administration can also be effected by means of subcutaneous, intramuscular, or intradermal injection.
  • injectable pharmaceutical formulations are commonly based upon injectable sterile saline, phosphate-buffered saline, oleaginous suspensions, or other injectable carriers known in the at and are generally rendered sterile and isotonic with the blood.
  • the injectable pharmaceutical formulations may therefore be provided as a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, including 1,3-butanediol, water.
  • injectable pharmaceutical formulations are formulated according to the known art using suitable dispersing or setting agents and suspending agents. Injectable compositions will generally contain from 0.1 to 5% w/w of a compound of the invention.
  • Solid dosage forms for oral administration of the compounds include capsules, tablets, pills, powders, and granules.
  • a pharmaceutically acceptable composition containing a compound(s) of the invention is formed by the incorporation of any of the normally employed excipients, such as, for example, pharmaceutical grades of mannitol, lactose, starch, pregelatinized starch, magnesium stearate, sodium saccharine, talcum, cellulose ether derivatives, glucose, gelatin, sucrose, citrate, propyl gallate, and the like.
  • Such solid pharmaceutical formulations may include formulations, as are well known in the art, to provide prolonged or sustained delivery of the drug to the gastrointestinal tract by any number of mechanisms, which include, but are not limited to, pH sensitive release from the dosage form based on the changing pH of the small intestine, slow erosion of a tablet or capsule, retention in the stomach based on the physical properties of the formulation, bioadhesion of the dosage form to the mucosal lining of the intestinal tract, or enzymatic release of the active drug from the dosage form.
  • Liquid dosage forms for oral administration of the compounds include emulsions, microemulsions, solutions, suspensions, syrups, and elixirs, optionally containing pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol and the like. These compositions can also contain additional adjuvants such as wetting, emulsifying, suspending, sweetening, flavoring, and perfuming agents.
  • a carrier such as, for example, water, saline, aqueous dextrose, glycerol, ethanol and the like.
  • additional adjuvants such as wetting, emulsifying, suspending, sweetening, flavoring, and perfuming agents.
  • Topical dosage forms of the compounds include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, eye ointments, eye or ear drops, impregnated dressings and aerosols, and may contain appropriate conventional additives such as preservatives, solvents to assist drug penetration and emollients in ointments and creams. Topical application may be once or more than once per day depending upon the usual medical considerations.
  • preferred compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles.
  • the formulations may also contain compatible conventional carriers, such as cream or ointment bases and ethanol or oleyl alcohol for lotions. Such carriers may be present as from about 1% up to about 98% of the formulation, more usually they will form up to about 80% of the formulation.
  • Transdermal administration is also possible.
  • Pharmaceutical compositions suitable for transdermal administration can be presented as discrete patches adapted to remain in intimate contact with the epidermis of the recipient for a prolonged period of time.
  • the dosage administration will, of course, be continuous rather than intermittent throughout the d osage regimen.
  • patches suitably contain a compound of the invention in an optionally buffered, aqueous solution, dissolved and/or dispersed in an adhesive, or dispersed in a polymer.
  • a suitable concentration of the active compound is about 1% to 35%, preferably about 3% to 15%.
  • the compounds of the invention are conveniently delivered in the form of an aerosol spray from a pump spray device not requiring a propellant gas or from a pressurized pack or a nebulizer with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, tetrafluoroethane, heptafluoropropane, carbon dioxide, or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, tetrafluoroethane, heptafluoropropane, carbon dioxide, or other suitable gas.
  • the aerosol spray dosage unit may be determined by providing a valve to deliver a metered amount so that the resulting metered dose inhaler (MDI) is used to administer the compounds of the invention in
  • Such inhaler, nebulizer, or atomizer devices are known in the art, for example, in PCT International Publication Nos. WO 97/12687 (particularly Figure 6 thereof, which is the basis for the com:mercia1 RFZPZIATO nebulizer); WO 94/07607; WO 97/12683; and WO 97/20590, to which reference is hereby made.
  • Rectal administration can be effected utilizing unit dose suppositories in which the compound is admixed with low-melting water-soluble or insoluble solids such as fats, cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, mixtures of polyethylene glycols of various molecular weights, or fatty acid esters of polyethylene glycols, or the like.
  • the active compound is usually a minor component, often from about 0.05 to 10% by weight, with the remainder being the base component.
  • the compounds of the invention are formulated with an acceptable carrier or excipient.
  • the carriers or excipients used must, of course, be acceptable in the sense of being compatible with the other ingredients of the composition and must not be deleterious to the patient.
  • the carrier or excipient can be a solid or a liquid, or both, and is preferably formulated with the compound of the invention as a unit-dose composition, for example, a tablet, which can contain from 0.05% to 95% by weight of the active compound.
  • Such carriers or excipients include inert fillers or diluents, binders, lubricants, disintegrating agents, solution retardants, resorption accelerators, absorption a gents, and coloring agents.
  • Suitable binders include starch, gelatin, natural sugars such as glucose or ⁇ -lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like.
  • Lubricants include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like.
  • Disintegrators include starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.
  • a therapeutically effective daily dose is from about 0.001 mg to about 15 mg/kg of body weight per day of a compound of the invention; preferably, from about 0.1 mg to about 10 mg/kg of body weight per day; and most preferably, from about 0.1 mg to about 1.5 mg/kg of body weight per day.
  • the dosage range would be from about 0.07 mg to about 1050 mg per day of a compound of the invention, preferably from about 7.0 mg to about 700 mg per day, and most preferably from about 7.0 mg to about 105 mg per day.
  • compositions encompass all the foregoing additives and the like.
  • the active substance, corn starch, lactose, and polyvinylpyrrolidone are thoroughly mixed and moistened with water.
  • the moist mass is pushed through a screen with a 1 mm mesh size, dried at about 45°C and the granules are then passed through the same screen.
  • convex tablet cores with a diameter of 6 mm are compressed in a tablet-making machine.
  • the tablet cores thus produced are coated in known manner with a covering consisting essentially of sugar and talc.
  • the finished coated tablets are polished with wax.
  • the substance and corn starch are mixed and moistened with water.
  • the moist mass is screened and dried.
  • the dry granules are screened and mixed with magnesium stearate.
  • the finished mixture is packed into size 1 hard gelatine capsules.
  • the active substance is dissolved in water at its own pH or optionally at pH 5.5 to 6.5 and sodium chloride is added to make it isotonic.
  • the solution obtained is filtered free from pyrogens and the filtrate is transferred under aseptic conditions into ampoules which are then sterilized and sealed by fusion.
  • the ampoules contain 5 mg, 25 mg, and 50 mg of active substance.
  • the suspension is transferred into a conventional aerosol container with a metering valve. Preferably, 50 ⁇ L of suspension are delivered per spray.
  • the active substance may also be metered in higher doses if desired (e.g., 0.02% by weight).
  • POWDER FOR INHALATION Component Amount active substance 1.0 mg lactose monohydrate to 5 mg

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)

Claims (21)

  1. Verbindung der Formel (I),
    Figure imgb0136
     worin:
    R1 eine Aryl- oder Heteroarylgruppe darstellt, jeweils gegebenenfalls unabhängig substituiert mit 1 bis 3 Substituentengruppen,
    worin jede Substituentengruppe von R1 unabhängig ist: C1-C5-Alkyl, C2-C5-Alkenyl, C2-C5-Alkinyl, C3-C8-Cycloalkyl, Aryl, C1-C5-Alkoxy, Aryloxy, C1-C5-Alkanoyl, Aroyl, C1-C5-Alkoxycarbonyl, C1-C5-Alkanoyloxy, Aminocarbonyloxy, C1-C5-Alkylaminocarbonyloxy, Aminocarbonyl, C1-C5-Alkylaminocarbonyl, C1-C5-Alkanoylamino, C1-C5-Alkoxycarbonylamino, C1-C5-Alkylsulfonylamino, C1-C5-Alkylaminosulfonyl, Halogen, Hydroxy, Carboxy, Cyano, Trifluormethyl, Nitro, Amino, worin das Stickstoffatom gegebenenfalls unabhängig mono- oder disubstituiert ist durch: C1-C5-Alkyl oder Aryl; oder Ureido, worin jedes Stickstoffatom gegebenenfalls unabhängig substituiert ist mit C1-C5-Alkyl; oder C1-C5-Alkylthio, worin das Schwefelatom gegebenenfalls zu einem Sulfoxid oder Sulfon oxidiert ist,
    worin jede Substituentengruppe von R1 gegebenenfalls unabhängig substituiert ist mit ein bis drei Substituentengruppen, ausgewählt aus Methyl, Halogen, Hydroxy, Oxo, Cyano, Trifluormethyl und Amino;
    R2 und R3 jeweils unabhängig Wasserstoff oder C1-C5-Alkyl sind, oder R2 und R3 zusammen mit dem Kohlenstoffatom, mit dem sie gemeinsam verknüpft sind, einen C3-C8-Spirocycloalkyl-Ring bilden;
    R4 CH2 oder C=O ist;
    R5 einen Carbocyclus, Heterocyclyl, Aryl, Heteroaryl, Carbocyclus-C1-C8-Alkyl, Aryl-C1-C8-Alkyl, Aryl-C1-C8-Haloalkyl, Heterocyclyl-C1-C8-Alkyl, Heteroaryl-C1-C8-Alkyl, Carbocyclus-C2-C8-Alkenyl, Aryl-C2-C8-Alkenyl, Heterocyclyl-C2-C8-Alkenyl oder Heteroaryl-C2-C8-Alkenyl darstellt, jeweils gegebenenfalls unabhängig substituiert mit ein bis drei Substituentengruppen,
    worin jede Substituentengruppe von R5 unabhängig ist: C1-C5-Alkyl, C2-C5-Alkenyl, C2-C5-Alkinyl, C3-C8-Cycloalkyl, Phenyl, C1-C5-Alkoxy, Phenoxy, C1-C5-Alkanoyl, Aroyl, C1-C5-Alkoxycarbonyl, C1-C5-Alkanoyloxy, Aminocarbonyloxy, C1-C5-Alkylaminocarbonyloxy, Aminocarbonyl, C1-C5-Alkylaminocarbonyl, C1-C5-Alkanoylamino, C1-C5-Alkoxycarbonylamino, C1-C5-Alkylsulfonylamino, C1-C5-Alkylaminosulfonyl, Halogen, Hydroxy, Carboxy, Cyano, Trifluormethyl, Nitro, Amino, worin das Stickstoffatom gegebenenfalls unabhängig mono- oder disubstituiert ist mit C1-C5-Alkyl; oder Ureido, worin jedes Stickstoffatom gegebenenfalls unabhängig substituiert ist mit C1-C5-Alkyl; oder C1-C5-Alkylthio, worin das Schwefelatom gegebenenfalls zu einem Sulfoxid oder Sulfon oxidiert ist; und
    R6 eine Arylgruppe ist, gegebenenfalls unabhängig substituiert mit ein bis drei Substituentengruppen, oder Gruppe A oder Gruppe B darstellt:
    Figure imgb0137
     worin jede Substituentengruppe von R6 unabhängig ist: C1-C5-Alkyl, C2-C5-Alkenyl, C2-C5-Alkinyl, C3-C8-Cycloalkyl, C1-C5-Alkoxy, C1-C5-Alkanoyl, C1-C5-Alkoxycarbonyl, C1-C5-Alkanoyloxy, Aminocarbonyloxy, C1-C5-Alkylaminocarbonyloxy, Aminocarbonyl, C1-C5-Alkylaminocarbonyl, C1-C5-Alkanoylamino, C1-C5-Alkoxycarbonylamino, C1-C5-Alkylsulfonylamino, C1-C5-Alkylaminosulfonyl, Halogen, Hydroxy, Carboxy, Cyano, Trifluormethyl, Nitro, Amino, worin das Stickstoffatom gegebenenfalls unabhängig mono- oder disubstituiert mit C1-C5-Alkyl ist; oder Ureido, worin jedes Stickstoffatom gegebenenfalls unabhängig substituiert mit C1-C5-Alkyl ist; oder C1-C5-Alkylthio, worin das Schwefelatom gegebenenfalls zu einem Sulfoxid oder Sulfon oxidiert ist;
    oder ein Tautomer, Ester, Amid oder Salz hiervon.
  2. Verbindung der Formel (I) nach Anspruch 1, worin:
    R1 Phenyl, Naphthyl, Indanyl, Indenyl, Chromanyl, Dihydrobenzofuranyl, Dihydroindolyl, Dihydrochinolinyl, Dihydroisochinolinyl, Tetrahydrochinolinyl, Tetrahydroisochinolinyl, Thienyl, Furanyl, Pyrrolyl, Pyridinyl, Pyrazinyl, Pyrimidinyl, Pyrazinyl, Indolyl, Benzofuranyl oder Benzothienyl ist, jeweils gegebenenfalls unabhängig substituiert mit ein bis drei Substituentengruppen,
    worin jede Substituentengruppe von R1 unabhängig ist: C1-C3-Alkyl, C2-C3-Alkenyl, C2-C3-Alkinyl, C1-C3-Alkoxy, C1-C3-Alkanoyl, C1-C3-Alkanoylamino, Halogen, Hydroxy, Cyano, Trifluormethyl oder Amino, worin das Stickstoffatom gegebenenfalls unabhängig mono- oder disubstituiert ist mit C1-C3-Alkyl; oder C1-C3-Alkylthio, worin das Schwefelatom gegebenenfalls zu einem Sulfoxid oder Sulfon oxidiert ist,
    worin jede Substituentengruppe von R1 gegebenenfalls unabhängig substituiert ist mit ein bis drei Substituentengruppen, ausgewählt aus Methyl, Fluor, Chlor, Brom, Hydroxy, Oxo, Cyano, Trifluormethyl und Amino;
    R2 und R3 jeweils unabhängig C1-C3-Alkyl sind oder R2 und R3 zusammen mit dem Kohlenstoffatom, mit dem sie gemeinsam verknüpft sind, einen C3-C6-Spirocycloalkyl-Ring bilden;
    R4 CH2 oder C=O ist;
    R5 Cyclopropyl, Cyclobutyl, Cyclopentyl, Cyclohexyl, Cyclopentylmethyl, Cyclohexylmethyl, Benzyl, Cyclopentylethyl, Cyclohexylethyl, Phenethyl oder Phenyldifluormethyl ist, jeweils gegebenenfalls unabhängig substituiert mit ein bis drei Substituentengruppen,
    worin jede Substituentengruppe von R5 unabhängig ist: Methyl, Methoxy, Hydroxy, Halogen, Cyano oder Trifluormethyl; und
    R6 eine Phenylgruppe ist, gegebenenfalls unabhängig substituiert mit ein bis drei Substituentengruppen oder Gruppe A oder Gruppe B darstellt:
    Figure imgb0138
     worin jede Substituentengruppe von R6 unabhängig ist: Methyl, Methoxy, Halogen, Cyano oder Trifluormethyl,
    oder ein Tautomer, Ester, Amid oder Salz hiervon.
  3. Verbindung der Formel (I) nach Anspruch 1, worin R2 und R3 zusammen mit dem Kohlenstoffatom, mit dem sie gemeinsam verknüpft sind, einen C3-C8-Spirocycloalkyl-Ring bilden.
  4. Verbindung der Formel (I) nach Anspruch 1, worin R2 und R3 jeweils unabhängig Wasserstoff oder C1-C5-Alkyl darstellen.
  5. Verbindung der Formel (I) nach Anspruch 1, worin R4 CH2 darstellt.
  6. Verbindung der Formel (I) nach Anspruch 1, worin R4 C=O darstellt.
  7. Verbindung der Formel (I) nach Anspruch 1, worin R6 eine Arylgruppe darstellt, gegebenenfalls substituiert mit ein bis drei Substituentengruppen, und worin jede Substituentengruppe von R6 unabhängig ist: C1-C5-Alkyl, C2-C5-Alkenyl, C2-C5-Alkinyl, C3-C8-Cycloalkyl, C1-C5-Alkoxy, C1-C5-Alkanoyl, C1-C5-Alkoxycarbonyl, C1-C5-Alkanoyloxy, C1-C5-Alkylaminocarbonyloxy, C1-C5-Alkylaminocarbonyl, C1-C5-Alkanoylamino, C1-C5-Alkoxycarbonylainino, C1-C5-Alkylsulfonylamino, C1-C5-Alkylaminosulfonyl, Halogen, Hydroxy, Carboxy, Cyano, Trifluormethyl, Nitro, Amino, worin das Stickstoffatom gegebenenfalls unabhängig mono- oder disubstituiert ist durch: C1-C5-Alkyl; oder Ureido, worin jedes Stickstoffatom gegebenenfalls unabhängig substituiert ist mit C1-C5-Alkyl; oder C1-C5-Alkylthio, worin das Schwefelatom gegebenenfalls zu einem Sulfoxid oder Sulfon oxidiert ist.
  8. Verbindung, ausgewählt aus:
    2-Benzyl-2-hydroxy-4-methyl-4-phenylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Hydroxy-4-methyl-2,4-diphenylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)-amid;
    2-Hydroxy-4-methyl-2-phenethyl-4-phenylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Hydroxy-2-(3-methoxybenzyl)-4-methyl-4-phenylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Hydroxy-2-(4-methoxybenzyl)-4-methyl-4-phenylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Hydroxy-2-[2-(4-methoxyphenyl)ethyl]-4-methyl-4-phenylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Cyclohexylmethyl-2-hydroxy-4-methyl-4-phenylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(4-tert-Butylbenzyl)-2-hydroxy-4-methyl-4-phenylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Biphenyl-4-ylmethyl-2-hydroxy-4-methyl-4-phenylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Hydroxy-4-methyl-2-naphthalin-2-ylmethyl-4-phenylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Hydroxy-2-(3-hydroxybenzyl)-4-methyl-4-phenylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Hydroxy-4-methyl-2-(2-methyl-2-phenylpropyl)-4-phenylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Benzyl-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Cyclohexylmethyl-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure-(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Benzyl-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Cyclohexylmethyl-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    4-(5-Fluor-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-(2-methyl-2-phenylpropyl)-pentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(2-Chlor-6-fluorbenzyl)-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methyl-pentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(3-Fluorbenzyl)-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(2-Fluorbenzyl)-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(3,4-Difluorbenzyl)-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure-(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(2-Chlor-6-fluorbenzyl)-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methyl-pentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(3-Fluorbenzyl)-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(2-Fluorbenzyl)-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(3,4-Difluorbenzyl)-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure-(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(4-Fluorbenzyl)-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    4-(5-Fluor-2-methoxyphenyl)-2-hydroxy-4-methyl-2-(3-methylbenzyl)pentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(4-Fluorbenzyl)-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    4-(5-Fluor-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-(3-methylbenzyl)pentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(3,5-Difluorphenyl)-4-(S-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure-(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Benzyl-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure(4-methyl-1-oxo-1H-benzo-[d] [1;2]-oxazin-6-yl)amid;
    2-Benzyl-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(4-methyl-1-oxo-1H-benzo-[d] [1,2]-oxazin-6-yl)amid;
    2-Cyclohexylmethyl-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure-(4-methyl-1-oxo-1H-benzo-[d] [1,2]-oxazin-6-yl)amid;
    2-Benzyl-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure(3,5-dichlorphenyl)amid;
    4-(5-Fluor-2-methoxyphenyl)-2-hydroxy-4-methyl-2-(2-methylbenzyl)pentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(3,5-Dimethylbenzyl)-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(2,5-Difluorbenzyl)-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure-(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(2,5-Difluorbenzyl)-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure-(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    4-(5-Fluor-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-(2-methylbenzyl)pentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(3,5-Dimethylbenzyl)-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Cyclohexylmethyl-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure-(3,5-dichlorphenyl)amid;
    2-Cyclohexylmethyl-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(4-methyl-1-oxo-1H-benzo-[d] [1,2]-oxazin-6-yl)amid;
    2-Benzyl-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(3,5-dichlorphenyl)amid;
    2-Cyclohexylmethyl-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure-(3,5-dichlorphenyl)amid;
    2-Benzyl-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäurephenylamid;
    2-Cyclohexylmethyl-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäurephenylamid;
    2-(3-Chlorbenzyl)-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    4-(5-Fluor-2-methoxyphenyl)-2-hydroxy-2-[2-(4-methoxyphenyl)ethyl]-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    4-(5-Fluor-2-methoxyphenyl)-2-hydroxy-2-(2-methoxybenzyl)-4-methylpentansäure-(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Benzyl-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäurephenylamid;
    2-Cyclohexylmethyl-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäurephenylamid;
    4-(5-Fluor-2-methoxyphenyl)-2-hydroxy-4-methyl-2-phenethylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(2-Chlorbenzyl)-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    4-(5-Fluor-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-phenethylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    4-(5-Fluor-2-hydroxyphenyl)-2-hydroxy-2-[2-(4-hydroxyphenyl)ethyl]-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(2-Chlorbenzyl)-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    4-(5-Fluor-2-hydroxyphenyl)-2-hydroxy-2-(2-hydroxybenzyl)-4-methylpentansäure-(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(2-Brombenzyl)-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(2-Brombenzyl)-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Benzyl-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure(3,5-dimethylphenyl)amid;
    2-Cyclohexylmethyl-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure (3,5-dimethylphenyl)amid;
    2-Benzyl-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure(3,5-bistrifluormethylphenyl)amid;
    2-Cyclohexylmethyl-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure-(3,5-bis-trifluormethylphenyl)amid;
    2-Benzyl-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure(3,5-dimethoxyphenyl)amid;
    2-Cyclohexylmethyl-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure-(3,5-dimethoxyphenyl)amid;
    2-Benzyl-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(3,5-dimethylphenyl)amid;
    2-Cyclohexylmethyl-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure-(3,5-dimethylphenyl)amid;
    2-Benzyl-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(3,5-bistrifluormethylphenyl)amid;
    2-Cyclohexylmethyl-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure-(3,5-bis-trifluormethylphenyl)amid;
    2-Benzyl-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(3,5-dihydroxyphenyl)amid;
    2-Cyclohexylmethyl-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure-(3,5-dihydroxyphenyl)amid;
    2-(5-Fluor-2-methoxybenzyl)-2-hydroxy-4-methyl-4-phenylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(5-Fluor-2-hydroxybenzyl)-2-hydroxy-4-methyl-4-phenylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(5-Fluor-2-methoxybenzyl)-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(5-Fluor-2-hydroxybenzyl)-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(3,5-Dimethoxybenzyl)-2-hydroxy-4-methyl-4-phenylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(3,5-Dihydroxybenzyl)-2-hydroxy-4-methyl-4-phenylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Hydroxy-2-(2-methoxybenzyl)-4-methyl-4-phenylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Hydroxy-2-(2-hydroxybenzyl)-4-methyl-4-phenylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Hydroxy-2-[2-(4-hydroxyphenyl)ethyl]-4-methyl-4-phenylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    5-[2-Benzyl-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentylamino]-3H-isobenzofuran-1-on;
    2-Benzyl-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure(4-cyano-3-trifluormethylphenyl)amid;
    2-Benzyl-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(4-cyano-3-trifluormethylphenyl)amid;
    4-(5-Fluor-2-methoxyphenyl)-2-hydroxy-4-methyl-2-(1-phenylvinyl)pentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Hydroxy-4-methyl-4-phenyl-2-pyridin-2-ylmethylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    4-(5-Fluor-2-methoxyphenyl)-2-hydroxy-4-methyl-2-(1-phenylethyl)pentansäure(1-oxo-1,3-dihydroisobenzofuran-S-yl)amid;
    4-(5-Fluor-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-(1-phenylethyl)pentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Benzyl-2-hydroxy-4-methyl-4-phenylpentansäure(4-methyl-1-oxo-1H-benzo-[d] [1,2]-oxazin-6-yl)amid;
    2-Cyclohexylmethyl-2-hydroxy-4-methyl-4-phenylpentansäure(4-methyl-1-oxo-1H-benzo- [d][1,2]-oxazin-6-yl)amid;
    2-Cyclohexylmethyl-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure-(4-cyano-3-trifluormethylphenyl)amid;
    2-Cyclopentyl-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Cyclopentyl-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Cyclopentylmethyl-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure-(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid; und
    2-Benzyl-2-hydroxy-N-(1-oxo-1,3-dihydroisobenzofuran-5-yl)-4-phenyl-butyramid
    oder die Tautomeren, Ester, Amide, Solvate oder Salze hiervon.
  9. Verbindung, ausgewählt aus:
    2-Benzyl-2-hydroxy-4-methyl-4-phenylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Hydroxy-4-methyl-2-phenethyl-4-phenylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Hydroxy-2-(3-methoxybenzyl)-4-methyl-4-phenylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Hydroxy-2-[2-(4-methoxyphenyl)ethyl]-4-methyl-4-phenylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Cyclohexylmethyl-2-hydroxy-4-methyl-4-phenylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(4-tert-Butylbenzyl)-2-hydroxy-4-methyl-4-phenylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Hydroxy-2-(3-hydroxybenzyl)-4-methyl-4-phenylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Hydroxy-4-methyl-2-(2-methyl-2-phenylpropyl)-4-phenylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Benzyl-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure(1-Oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Cyclohexylmethyl-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Benzyl-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Cyclohexylmethyl-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    4-(5-Fluor-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-(2-methyl-2-phenylpropyl)-pentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(2-Chlor-6-fluorbenzyl)-4-(5-fluor-2-methoxyphenyl)-2-Hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(3-Fluorbenzyl)-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(2-Fluorbenzyl)-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(3,4-Difluorbenzyl)-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(2-Chlor-6-fluorbenzyl)-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(3-Fluorbenzyl)-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(2-Fluorbenzyl)-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(3,4-Difluorbenzyl)-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(4-Fluorbenzyl)-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(4-Fluorbenzyl)-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    4-(5-Fluor-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-(3-methylbenzyl)pentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Benzyl-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure(4-methyl-1-oxo-1H-benzo-[d] [1,2]-oxazin-6-yl)amid;
    2-Benzyl-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(4-methyl-1-oxo-1H-benzo-[d] [1,2]-oxazin-6-yl)amid;
    2-Cyclohexylmethyl-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure-(4-methyl-1-oxo-1H-benzo-[d][1 ,2]-oxazin-6-yl)amid;
    2-Benzyl-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure(3,5-dichlorphenyl)amid;
    4-(5-Fluor-2-methoxyphenyl)-2-hydroxy-4-methyl-2-(2-methylbenzyl)pentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(2,5-Difluorbenzyl)-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure-(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(2,5-Difluorbenzyl)-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure-(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    4-(5-Fluor-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-(2-methylbenzyl)pentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Cyclohexylmethyl-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure-(3,5-dichlorphenyl)amid;
    2-Cyclohexylmethyl-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(4-methyl-1-oxo-1H-benzo-[d] [1,2]-roxazin-6-yl)amid;
    2-Cyclohexylmethyl-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure (3,5-dichlorphenyl)amid;
    2-(3-Chlorbenzyl)-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    4-(5-Fluor-2-methoxyphenyl)-2 hydroxy-2-(2-methoxybenzyl)-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    4-(5-Fluor-2-methoxyphenyl)-2-hydroxy-4-methyl-2-phenethylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(2-Chlorbenzyl)-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    4-(5-Fluor-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-phenethylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    4-(5-Fluor-2-hydroxyphenyl)-2-hydroxy-2-[2-(4-hydroxyphenyl)ethyl]-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(2-Chlorbenzyl)-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    4-(5-Fluor-2-hydroxyphenyl)-2-hydroxy-2-(2-hydroxybenzyl)-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(2-Brombenzyl)-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(2-Brombenzyl)-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Cyclohexylmethyl-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure-(3,5-bis-trifluormethylphenyl)amid;
    2-Hydroxy-2-(2-methoxybenzyl)-4-methyl-4-phenylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Hydroxy-2-(2-hydroxybenzyl)-4-methyl-4-phenylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    5-[2-Benzyl-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentylamino]-3H-isobenzofuran-1-on;
    2-Benzyl-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure(4-cyano-3-trifluormethylphenyl)amid;
    2-Benzyl-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(4-cyano-3-trifluormethylphenyl)amid;
    4-(5-Fluor-2-methoxyphenyl)-2-hydroxy-4-methyl-2-(1-phenylvinyl)pentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    4-(5-Fluor-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-(1-phenylethyl)pentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Benzyl-2-hydroxy-4-methyl-4-phenylpentansäure(4-methyl-1-oxo-1H-benzo-[d] [1,2]-oxazin-6-yl)amid;
    2-Cyclohexylmethyl-2-hydroxy-4-methyl-4-phenylpentansäure(4-methyl-1-oxo-1H-benzo-[d] [1,2]-oxazin-6-yl)amid;
    2-Cyclohexylmethyl-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure-(4-cyano-3-trifluormethylphenyl)amid;
    2-Cyclopentyl-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Cyclopentyl-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid; und
    2-Cyclopentylmethyl-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure-(1-oxo-1,3-dihydroisobenzofuran-5-yl)ainid,
    oder die Tautomeren, Ester, Amide, Solvate oder Salze hiervon.
  10. Verbindung, ausgewählt aus:
    2-Benzyl-2-hydroxy-4-methyl-4-phenylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Cyclohexylmethyl-2-hydroxy-4-methyl-4-phenylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Hydroxy-4-methyl-2-(2-methyl-2-phenylpropyl)-4-phenylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Benzyl-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Cyclohexylmethyl-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Cyclohexylmethyl-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(3-Fluorbenzyl)-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(2-Fluorbenzyl)-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(2-Fluorbenzyl)-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(3,4-Difluorbenzyl)-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(4-Fluorbenzyl)-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Benzyl-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure(4-methyl-1-oxo-1H-benzo-[d][1,2]-oxazin-6-yl)amid;
    2-Benzyl-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(4-methyl-1-oxo-1H-benzo-[d][1,2]-oxazin-6-yl)amid;
    2-Cyclohexylmethyl-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure(4-methyl-1-oxo-1H-benzo-[d][1,2]-oxazin-6-yl)amid;
    4-(5-Fluor-2-methoxyphenyl)-2-hydroxy-4-methyl-2-(2-methylbenzyl)pentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    4-(5-Fluor-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-(2-methylbenzyl)pentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Cyclohexylmethyl-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(4-methyl-1-oxo-1H-benzo-[d][1,2]-oxazin-6-yl)amid;
    2-(2-Chlorbenzyl)-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    4-(5-Fluor-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-phenethylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(2-Chlorbenzyl)-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    4-(5-Fluor-2-hydroxyphenyl)-2-hydroxy-2-(2-hydroxybenzyl)-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(2-Brombenzyl)-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-(2-Brombenzyl)-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    5-[2-Benzyl-4-(5-fluor-2-methoxyphenyl)-2-hydroxy-4-methylpentylamino]-3H-isobenzofuran-1-on;
    4-(5-Fluor-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-(1-phenylethyl)pentansäure(1 - oxo-1,3-dihydroisobenzofuran-5-yl)amid;
    2-Benzyl-2-hydroxy-4-methyl-4-phenylpentansäure(4-methyl-1-oxo-1H-benzo-[d] [1,2]-oxazin-6-yl)amid;
    2-Cyclohexylmethyl-2-hydroxy-4-methyl-4-phenylpentansäure(4-methyl-1-oxo-1H-benzo-[d] [1,2]-oxazin-6-yl)amid;
    2-Cyclopentyl-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid; und
    2-Cyclopentylmethyl-4-(5-fluor-2-hydroxyphenyl)-2-hydroxy-4-methylpentansäure(1-oxo-1,3-dihydroisobenzofuran-5-yl)amid,
    oder die Tautomeren, Ester, Amide, Solvate oder Salze hiervon.
  11. Pharmazeutische Zusammensetzung, umfassend eine wirksame Menge einer Verbindung gemäß einem der Ansprüche 1 bis 10 oder eines Tautomeren, Esters, Amids, Solvats oder Salzes hiervon sowie einen pharmazeutisch akzeptablen Hilfsstoff oder Träger.
  12. Verwendung einer Verbindung nach einem der Ansprüche 1 bis 10 oder eines Tautomeren, Esters, Amids, Solvats oder Salzes hiervon für die Herstellung einer Arzneimittelzusammensetzung, um die Glucocorticoid-Rezeptorfunktion eines Patienten zu modulieren.
  13. Verwendung einer Verbindung nach einem der Ansprüche 1 bis 10 oder eines Tautomeren, Esters, Amids, Solvats oder Salzes hiervon für die Herstellung einer pharmazeutischen Zusammensetzung, um einen Krankheitszustand oder einen durch die Glucocorticoid-Rezeptorfunktion vermittelten Zustand zu behandeln.
  14. Verwendung einer Verbindung nach einem der Ansprüche 1 bis 10 oder eines Tautomeren, Esters, Amids, Solvats oder Salzes hiervon für die Herstellung einer pharmazeutischen Zusammensetzung, um einen Krankheitszustand oder Zustand, ausgewählt aus: Typ-II-Diabetes, Obesität, kardiovaskuläre Erkrankungen, Hypertonie, Arteriosklerose, neurologische Erkrankungen, Nebennieren- und hypophysäre Tumore und Glaukoma, zu behandeln.
  15. Verwendung einer Verbindung nach einem der Ansprüche 1 bis 10 oder eines Tautomeren, Esters, Amids, Solvats oder Salzes hiervon für die Herstellung einer pharmazeutischen Zusammensetzung, um eine Krankheit, charakterisiert durch entzündliche, allergische oder proliferative Prozesse, zu behandeln.
  16. Verwendung nach Anspruch 15, worin die Erkrankung ausgewählt ist aus: (i) Lungenerkrankungen; (ii) rheumatische Erkrankungen oder Autoimmunerkrankungen oder Gelenkerkrankungen; (iii) allergische Erkrankungen; (iv) Vaskulitis-Erkrankungen; (v) dermatologische Erkrankungen; (vi) renale Erkrankungen; (vii) Lebererkrankungen; (viii) gastrointestinale Erkrankungen; (ix) proktologische Erkrankungen; (x) Augenerkrankungen; (xi) Erkrankungen von Hals, Nase und Ohr (HNO-Bereich); (xii) neurologische Erkrankungen; (xiii) Bluterkrankungen; (xiv) Tumorerkrankungen; (xv) endokrine Erkrankungen; (xvi) Organ- und Gewebetransplantations- und Transplantat-versus-Wirts-Erkrankungen; (xvii) schwere Schockzustände; (xviii) Substitutionstherapie; und (xix) Schmerz aus Entzündungsgenese.
  17. Verwendung nach Anspruch 15, worin die Erkrankung ausgewählt ist aus: Typ-I-Diabetes, Osteoarthritis, Guillain-Barre-Syndrom, Restenose nach perkutaner transluminaler Koronarangioplastie, Alzheimer-Erkrankung, akutem und chronischem Schmerz, Atheriosklerose, Reperfusionsverletzung, Knochenresorptionserkrankungen, kongestiven Herzfehler bzw. Stauungsinsuffizienz, Myokard-Infarkt, thermische Verletzung, multiple Organverletzung nach Trauma, akute eitrige Meningitis, nekrotisierende Enterocolitis und Syndrome im Zusammenhang mit Hämodialyse, Leukopherese und Granulozyt-Transfusion.
  18. Verfahren zur Herstellung einer Verbindung der Formel (I)
    Figure imgb0139
     worin R1, R2, R3, R5 und R6 wie in Anspruch 1 definiert sind, und R4 C=O ist, wobei das Verfahren umfasst:
    Umsetzen eines Amids der Formel (V) mit R5M, worin M Li oder MgX ist, und X Cl, Br oder I ist, in einem geeigneten Lösungsmittel, um die Verbindung der Formel (I) zu bilden, worin R4 C=O ist
    Figure imgb0140
  19. Verfahren zur Herstellung einer Verbindung der Formel (I)
    Figure imgb0141
     worin R1, R2, R3, R5 und R6 wie in Anspruch 1 definiert sind, und R4 CH2 ist, wobei das Verfahren umfasst:
    Umsetzen eines Aminoketons der Formel (X) mit R5M, worin M Li oder MgX ist, und X Cl, Br oder I ist, in einem geeigneten Lösungsmittel, um die Verbindung der Formel (I) zu bilden, worin R4 CH2 ist
    Figure imgb0142
  20. Verfahren zur Herstellung einer Verbindung der Formel (I)
    Figure imgb0143
     worin R1, R2, R3, R5 und R6 wie in Anspruch 1 definiert sind, und R4 C=O ist, wobei das Verfahren umfasst:
    a) Umsetzen einer Verbindung der Formel (II) mit Diethyloxalat in einem geeigneten Lösungsmittel, um einen Ketoester der Formel (III) zu bilden
    Figure imgb0144
    b) Hydrolysieren des Ketoesters der Formel (III), um eine Carboxylsäure der Formel (IV) zu bilden
    Figure imgb0145
    c) Koppeln der Carboxylsäure der Formel (IV) mit einem Amin R6NH2 unter Verwendung geeigneter Kopplungsbedingungen, um ein Amid der Formel (V) zu bilden,
    Figure imgb0146
     und
    d) Umsetzen des Amids der Formel (V) mit R5M, worin M Li oder MgX ist, und X Cl, Br oder I ist, in einem geeigneten Lösungsmittel, um die Verbindung der Formel (I) zu bilden, worin R4 C=O ist,
    Figure imgb0147
     oder
    a') Umsetzen eines Arylbromids R1Br mit einem geeigneten organometallischen Reagens in einem geeigneten Lösungsmittel und Umsetzen des resultierenden Anions mit einem Keton, das R2 und R3 trägt, um einen Alkohol der Formel (VI) zu ergeben,
    Figure imgb0148
    b') Umsetzen des Alkohols der Formel (VI) mit dem Trimethylsilylenolether, abgeleitet aus Ethylpyruvat, in Gegenwart einer geeigneten Lewis-Säure, in einem geeigneten Lösungsmittel, um einen Ketoester der Formel (III) bereitzustellen,
    Figure imgb0149
    und Durchführen der Schritte (b), (c) und (d), wie oben dargestellt.
  21. Verfahren zur Herstellung einer Verbindung der Formel (I)
    Figure imgb0150
     worin R1, R2, R3, R5 und R6 wie in Anspruch 1 definiert sind, und R4 CH2 ist, wobei das Verfahren umfasst:
    a) Umsetzen eines Aryl- oder Heteroarylbromids mit einem geeigneten organometallischen Reagens in einem geeigneten Lösungsmittel und Behandeln des resultierenden Anions mit einer Lösung von Kupferiodid in Dimethylsulfid, gefolgt von einem Methylvinylketon der Formel (VII), das R2 und R3 trägt, um ein Methylketon der Formel (VIII) zu bilden,
    Figure imgb0151
    b) Umsetzen des Methylketons der Formel (VIII) mit einem geeigneten Bromierungsmittel, um ein Bromketon der Formel (IX) zu bilden,
    Figure imgb0152
    c) Umsetzen des Bromketons der Formel (IX) mit einem Amin R6NH2 in einem geeigneten Lösungsmittel, um ein Aminoketon der Formel (X) zu bilden,
    Figure imgb0153
     und
    d) Umsetzen des Aminoketons der Formel (X) mit R5 M, worin M Li oder MgX ist, und X Cl, Br oder I ist, in einem geeigneten Lösungsmittel, um die Verbindung der Formel (I) zu bilden, worin R4 CH2 ist
    Figure imgb0154
EP03701228A 2002-01-14 2003-01-03 Glucocorticoid mimetika, verfahren zu ihrer herstellung, pharmazeutische formulierungen sie enthaltend und verwendungen davon Expired - Lifetime EP1467982B8 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US34848602P 2002-01-14 2002-01-14
US348486P 2002-01-14
US37907802P 2002-05-09 2002-05-09
US379078P 2002-05-09
PCT/US2003/000300 WO2003059899A1 (en) 2002-01-14 2003-01-03 Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof

Publications (3)

Publication Number Publication Date
EP1467982A1 EP1467982A1 (de) 2004-10-20
EP1467982B1 true EP1467982B1 (de) 2006-11-22
EP1467982B8 EP1467982B8 (de) 2007-04-11

Family

ID=26995749

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03701228A Expired - Lifetime EP1467982B8 (de) 2002-01-14 2003-01-03 Glucocorticoid mimetika, verfahren zu ihrer herstellung, pharmazeutische formulierungen sie enthaltend und verwendungen davon

Country Status (9)

Country Link
US (2) US6960581B2 (de)
EP (1) EP1467982B8 (de)
JP (1) JP2005519897A (de)
AT (1) ATE346058T1 (de)
AU (1) AU2003202216A1 (de)
CA (1) CA2472746A1 (de)
DE (1) DE60309829T2 (de)
ES (1) ES2276038T3 (de)
WO (1) WO2003059899A1 (de)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003202216A1 (en) 2002-01-14 2003-07-30 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof
DK1490062T3 (da) 2002-03-26 2008-04-28 Boehringer Ingelheim Pharma Glukokortikoidmimetika, fremgangsmåder til fremstilling deraf, farmaceutiske sammensætninger og anvendelser deraf
EP1490317A1 (de) * 2002-03-26 2004-12-29 Boehringer Ingelheim Pharmaceuticals Inc. Glucocorticoid-mimetika, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische zusammensetzungen, und ihre verwendungen
US7186864B2 (en) * 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en) * 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US6858627B2 (en) 2002-08-21 2005-02-22 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
BR0313923A (pt) * 2002-08-29 2005-07-12 Boehringer Ingelheim Pharma Derivados de 3-(sulfonamidoetil)-indol para uso como miméticos de glicocorticóide no tratamento de doenças inflamatórias, alérgicas e proliferativas
WO2004063163A1 (en) * 2003-01-03 2004-07-29 Boehringer Ingelheim Pharmaceuticals, Inc. 1-propanol and 1-propylamine derivatives and their use as glucocorticoid ligands
US20040224992A1 (en) * 2003-02-27 2004-11-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
BRPI0412231A (pt) * 2003-07-01 2006-08-22 Schering Ag derivados de pentanol substituìdos heterociclicamente, processos para a sua preparação e sua aplicação como inibidores de inflamação
US20050090559A1 (en) * 2003-07-01 2005-04-28 Markus Berger Heterocyclically-substituted pentanol derivatives, process for their production and their use as anti-inflammatory agents
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
UY28526A1 (es) 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
WO2005040145A1 (en) * 2003-10-16 2005-05-06 Boehringer Ingelheim Pharmaceuticals, Inc. Stereoselective synthesis of certain trifluoromethyl-substituted alcohols
US7795272B2 (en) 2004-03-13 2010-09-14 Boehringer Ingelheim Pharmaceutical, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
JP2007530541A (ja) * 2004-03-22 2007-11-01 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド グルココルチコイドミメチックスとしてのα−トリフルオロメチルアルコール又はアミン
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
JP2008525525A (ja) * 2004-12-27 2008-07-17 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド グルココルチコイドミメティクス、その製法、医薬組成物及び使用
ATE517908T1 (de) 2005-01-10 2011-08-15 Glaxo Group Ltd Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände
PE20061351A1 (es) 2005-03-25 2007-01-14 Glaxo Group Ltd COMPUESTOS 8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA 2,4,8-TRISUSTITUIDOS COMO INHIBIDORES DE LA QUINASA CSBP/RK/p38
TW200724142A (en) 2005-03-25 2007-07-01 Glaxo Group Ltd Novel compounds
EP1893588A1 (de) * 2005-06-10 2008-03-05 Boehringer Ingelheim International GmbH Glucocorticoid-mimetika, verfahren zur herstellung davon, pharmazeutische zusammensetzungen und deren verwendung
DE102005030293A1 (de) * 2005-06-24 2007-01-04 Schering Ag Verwendung von nichtsteroidale Progesteronrezeptor-Modulatoren
US7408060B2 (en) 2005-06-24 2008-08-05 Schering Ag Nonsteroidal progesterone receptor modulators
DE102005030294A1 (de) * 2005-06-24 2007-01-04 Schering Ag Nichtsteroidale Progesteronrezeptor-Modulatoren
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
US8202546B2 (en) 2005-08-04 2012-06-19 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US8263137B2 (en) 2005-08-04 2012-09-11 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US7998500B2 (en) 2005-08-04 2011-08-16 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US7901710B2 (en) 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
KR101025139B1 (ko) * 2005-12-09 2011-03-31 에프. 호프만-라 로슈 아게 항염증제로서의 프로피온아미드 화합물
TW200730498A (en) 2005-12-20 2007-08-16 Glaxo Group Ltd Compounds
US8178573B2 (en) 2006-04-20 2012-05-15 Glaxo Group Limited Compounds
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
MX2008015151A (es) * 2006-07-07 2008-12-12 Bausch & Lomb Composiciones que comprenden un agonista del receptor glucocorticoide disociado y un agente inmunodepresor para tratar xeroftalmia.
AU2007284175A1 (en) * 2006-08-07 2008-02-21 Bausch & Lomb Incorporated Treating infections and sequelae thereof with combined dissociated' glucocorticoid receptor agonists and anti-infective agents
CA2661607C (en) 2006-08-31 2012-06-26 Bausch & Lomb Incorporated Compositions and methods for treating or preventing glaucoma or progression thereof
US20110104159A1 (en) * 2006-09-11 2011-05-05 Rohrs Brian R Compositions and methods for treating, controlling, reducing, ameliorating, or preventing allergy
US20110105559A1 (en) * 2006-09-11 2011-05-05 Rohrs Brian R Compositions and Methods for Treating, Controlling, Reducing, Ameliorating, or Preventing Allergy
DK2061444T3 (da) * 2006-09-11 2011-06-27 Bausch & Lomb Sammensætninger og fremgangsmåder til behandling, kontrol, reducering, forbedring eller forebyggelse af allergi
GB0620385D0 (en) 2006-10-13 2006-11-22 Glaxo Group Ltd Novel compounds
EP2089355A2 (de) 2006-11-01 2009-08-19 Brystol-Myers Squibb Company Modulatoren der glucocorticoidrezeptor-, ap-1- und/oder nf-kappa-b-aktivität und deren verwendung
JP2010512331A (ja) * 2006-12-06 2010-04-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルココルチコイド模倣薬、それらの製造方法、医薬組成物、及びこれらの使用
UY30805A1 (es) * 2006-12-21 2008-07-31 Bayer Schering Pharma Ag Moduladores no esteroides de receptores de progesterona
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
US20090042936A1 (en) * 2007-08-10 2009-02-12 Ward Keith W Compositions and Methods for Treating or Controlling Anterior-Segment Inflammation
US20090087443A1 (en) * 2007-09-27 2009-04-02 Bartels Stephen P Pharmacological Adjunctive Treatment Associated with Glaucoma Filtration Surgery
WO2009069736A1 (ja) * 2007-11-28 2009-06-04 Kyowa Hakko Kirin Co., Ltd. 含窒素化合物
DE102007058747A1 (de) * 2007-12-05 2009-06-10 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
US20090239836A1 (en) * 2008-03-24 2009-09-24 Mary Lee Ciolkowski Multifunctional Ophthalmic Compositions
US20090291073A1 (en) * 2008-05-20 2009-11-26 Ward Keith W Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same
EP2285803A4 (de) 2008-05-23 2011-10-05 Amira Pharmaceuticals Inc Hemmer des 5-lipoxygenase aktivierenden proteins
ATE552255T1 (de) 2008-06-05 2012-04-15 Glaxo Group Ltd 4-aminoindazole
JP5502858B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤として有用な４−カルボキサミドインダゾール誘導体
US8268859B2 (en) 2008-06-06 2012-09-18 Boehringer Ingelheim International Gmbh Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
JP5656880B2 (ja) 2009-03-09 2015-01-21 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
WO2010106016A1 (en) 2009-03-17 2010-09-23 Glaxo Group Limited Pyrimidine derivatives used as itk inhibitors
WO2010107952A2 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2408458A1 (de) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. Rna-schnittstellen-vermittelte unterdrückung der signal transducer and activator of transcription 6 (stat6) genexpression mit short interfering nucleic acid (sina)
WO2010107957A2 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
CN102439151A (zh) 2009-03-19 2012-05-02 默沙东公司 使用短干扰核酸（siNA）的RNA干扰介导的BTB和CNC同系物1，碱性亮氨酸拉链转录因子1（Bach1）基因表达的抑制
WO2010111464A1 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20120022142A1 (en) 2009-03-27 2012-01-26 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
US20120004281A1 (en) 2009-03-27 2012-01-05 Merck Sharp & Dohme Corp RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA)
JP2012521765A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いた細胞内接着分子１（ＩＣＡＭ−１）遺伝子発現のＲＮＡ干渉媒介性阻害
WO2010111490A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20110077270A1 (en) * 2009-04-21 2011-03-31 Pfeffer Bruce A Compositions and Methods for Treating Ocular Inflammation with Lower Risk of Increased Intraocular Pressure
EP2421834A1 (de) 2009-04-24 2012-02-29 Glaxo Group Limited Pyrazol- und triazolcarbonsäureamide als inhibitoren des crac-kanals
EP2421835A1 (de) 2009-04-24 2012-02-29 Glaxo Group Limited N-pyrazolylcarbonsäureamide als crac-kanal-inhibitoren
AU2010243613B2 (en) 2009-04-30 2015-05-07 Glaxo Group Limited Oxazole substituted indazoles as PI3-kinase inhibitors
US20110130591A1 (en) 2009-06-03 2011-06-02 Boehringer Ingelheim International Gmbh Steroselective synthesis of certain trifluoromethyl-substituted alcohols
US20100312013A1 (en) 2009-06-03 2010-12-09 Boehringer Ingelheim International Gmbh Steroselective synthesis of certain trifluoromethyl-substituted alcohols
US20110130578A1 (en) 2009-06-03 2011-06-02 Boehringer Ingelheim International Gmbh Stereoselective synthesis of certain trifluoromethyl-substituted alcohols
US20110130567A1 (en) 2009-06-03 2011-06-02 Boehringer Ingelheim International Gmbh Steroselective synthesis of certain trifluoromethyl-substituted alcohols
US20120238559A1 (en) 2009-12-03 2012-09-20 Glaxo Group Limited Novel compounds
WO2011067366A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
US20120245171A1 (en) 2009-12-03 2012-09-27 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of pi3 kinases
EP3020393B1 (de) 2009-12-16 2020-10-07 3M Innovative Properties Company Formulierungen und verfahren zur steuerung der mdi-partikelgrössenfreisetzung
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
US9126997B1 (en) * 2010-09-07 2015-09-08 Northwestern University Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
HUE026059T2 (en) 2010-09-08 2016-05-30 Glaxosmithkline Ip Dev Ltd N- [5- [4- (5 - {[(2R, 6S) -2,6-dimethyl-4-morpholinyl] methyl} -1,3-oxazol-2-yl) -1H-indazol-6-yl ] Polymorphs and salts of 2 - (methyloxy) -3-pyridinyl] methanesulfonamide
US9326987B2 (en) 2010-09-08 2016-05-03 Glaxo Group Limited Indazole derivatives for use in the treatment of influenza virus infection
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
EP2630127A1 (de) 2010-10-21 2013-08-28 Glaxo Group Limited Pyrazolverbindungen, gegen allergie-, entzündungs- und immunerkrankungen
EP2630126B1 (de) 2010-10-21 2015-01-07 Glaxo Group Limited Pyrazolverbindungen gegen allergie-, immun- und entzündungserkrankungen
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
US20140005188A1 (en) 2011-03-11 2014-01-02 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
US20120316199A1 (en) * 2011-06-07 2012-12-13 Ward Keith W Compositions and methods for treating, controlling, reducing, or ameliorating inflammatory pain
KR20160060100A (ko) 2013-09-22 2016-05-27 칼리토르 사이언시즈, 엘엘씨 치환된 아미노피리미딘 화합물 및 이용 방법
AU2014336251A1 (en) 2013-10-17 2016-04-14 Glaxosmithkline Intellectual Property Development Limited PI3K inhibitor for treatment of respiratory disease
RU2016112268A (ru) 2013-10-17 2017-11-22 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Ингибитор PI3K для лечения респираторного заболевания
JP6517319B2 (ja) 2014-03-28 2019-05-22 キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒ Ｓｃｉｅｎｃｅｓ， Ｌｌｃ 置換されたヘテロアリール化合物および使用方法
US20170100385A1 (en) 2014-05-12 2017-04-13 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions comprising danirixin for treating infectious diseases
EP3347097B1 (de) 2015-09-11 2021-02-24 Sunshine Lake Pharma Co., Ltd. Substituierte aminopyrimidin-derivate als modulatoren der kinasen jak, flt3 und aurora
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
US20190161480A1 (en) 2016-08-08 2019-05-30 Glaxosmithkline Intellectual Property Development Limited Chemical Compounds
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
US10683297B2 (en) 2017-11-19 2020-06-16 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
AU2019209960B2 (en) 2018-01-20 2023-11-23 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
WO2021191875A1 (en) 2020-03-26 2021-09-30 Glaxosmithkline Intellectual Property Development Limited Cathepsin inhibitors for preventing or treating viral infections

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8402755A (nl) 1983-09-22 1985-04-16 Sandoz Ag Azool-derivaten, werkwijze voor het bereiden daarvan, preparaten die ze bevatten, en toepassing daarvan.
GB8406000D0 (en) 1984-03-07 1984-04-11 Ici Plc Olefine derivatives
GB8617652D0 (en) 1986-07-18 1986-08-28 Ici Plc Acylanilide derivatives
GB8617653D0 (en) 1986-07-18 1986-08-28 Ici Plc Amide derivatives
US5039691A (en) 1989-06-08 1991-08-13 Marion Merrell Dow Inc. 5-(1-(imidazol)methyl)-3,3-disubstituted-2(3H)furanone derivatives
EP1382597A3 (de) 1994-12-22 2004-04-07 Ligand Pharmaceuticals, Inc. Steroidrezeptor-Modulator Verbindungen und Methoden
AU703203B2 (en) 1996-01-30 1999-03-18 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
DE19723722A1 (de) * 1997-05-30 1998-12-10 Schering Ag Nichtsteroidale Gestagene
HUP0100460A3 (en) 1998-02-13 2003-03-28 Ligand Pharmaceuticals Inc San Glucocorticoid-selective anti-inflammatory agents
US6506766B1 (en) 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
DE19856475A1 (de) 1998-11-27 2000-05-31 Schering Ag Nichtsteroidale Entzündungshemmer
EA004886B1 (ru) 1999-04-30 2004-08-26 Пфайзер Продактс Инк. Модуляторы рецепторов глюкокортикоидов
US6436986B1 (en) 1999-09-01 2002-08-20 Abbott Laboratories Glucocorticoid receptor antagonists for treatment of diabetes
US6329534B1 (en) 1999-09-01 2001-12-11 Abbott Laboratories Glucocorticoid receptor antagonists for treatment of diabetes
DE10038639A1 (de) 2000-07-28 2002-02-21 Schering Ag Nichtsteroidale Entzündungshemmer
DE60233111D1 (de) 2001-02-14 2009-09-10 Karobio Ab Glucocorticoid-rezeptoren-modulatoren
US6583180B2 (en) 2001-02-14 2003-06-24 Abbott Laboratories Glucocorticoid receptor modulators
AU2003202216A1 (en) 2002-01-14 2003-07-30 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof
DK1490062T3 (da) 2002-03-26 2008-04-28 Boehringer Ingelheim Pharma Glukokortikoidmimetika, fremgangsmåder til fremstilling deraf, farmaceutiske sammensætninger og anvendelser deraf
EP1490317A1 (de) 2002-03-26 2004-12-29 Boehringer Ingelheim Pharmaceuticals Inc. Glucocorticoid-mimetika, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische zusammensetzungen, und ihre verwendungen
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
BR0313923A (pt) 2002-08-29 2005-07-12 Boehringer Ingelheim Pharma Derivados de 3-(sulfonamidoetil)-indol para uso como miméticos de glicocorticóide no tratamento de doenças inflamatórias, alérgicas e proliferativas

Also Published As

Publication number Publication date
EP1467982B8 (de) 2007-04-11
CA2472746A1 (en) 2003-07-24
ES2276038T3 (es) 2007-06-16
EP1467982A1 (de) 2004-10-20
JP2005519897A (ja) 2005-07-07
DE60309829T2 (de) 2007-09-13
DE60309829D1 (de) 2007-01-04
US7189758B2 (en) 2007-03-13
AU2003202216A1 (en) 2003-07-30
US20060030561A1 (en) 2006-02-09
WO2003059899A1 (en) 2003-07-24
US6960581B2 (en) 2005-11-01
US20030232823A1 (en) 2003-12-18
ATE346058T1 (de) 2006-12-15

Similar Documents

Publication Publication Date Title
EP1467982B1 (de) Glucocorticoid mimetika, verfahren zu ihrer herstellung, pharmazeutische formulierungen sie enthaltend und verwendungen davon
US7074806B2 (en) Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7186864B2 (en) Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7795272B2 (en) Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
EP1490062B1 (de) Glucocorticoid-mimetika, deren herstellung, pharmazeutische zusammensetzungen und verwendung
EP1532113B1 (de) Substituierte dihydrochinoline als glucocorticoid-mmimetika,verfahren zu deren herstellung, pharmazeutische zubereitungen und deren verwendung
EP1836166B1 (de) Glucocorticoid-mimetika, verfahren zu deren herstellung, pharmazeutische zusammensetzungen und deren verwendung
US20040224992A1 (en) Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US20050234091A1 (en) Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
US20040029932A1 (en) Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US20090176807A1 (en) Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040816

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

17Q First examination report despatched

Effective date: 20040930

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061122

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061122

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061122

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061122

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061122

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061122

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070103

REF Corresponds to:

Ref document number: 60309829

Country of ref document: DE

Date of ref document: 20070104

Kind code of ref document: P

RIN2 Information on inventor provided after grant (corrected)

Inventor name: THOMSON, DAVID,BOEHRINGER INGELHEIM CORP.

Inventor name: ZINDELL, RENEE, M.,BOEHRINGER INGELHEIM CORP.

Inventor name: BETAGERI, RAJ,BOEHRINGER INGELHEIM CORP.

Inventor name: ZHANG, YAN,BOEHRINGER INGELHEIM CORP.

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070222

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070222

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070222

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070423

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2276038

Country of ref document: ES

Kind code of ref document: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20070823

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070223

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20080115

Year of fee payment: 6

Ref country code: ES

Payment date: 20080130

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20080122

Year of fee payment: 6

Ref country code: GB

Payment date: 20080124

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20080116

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20080111

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20080122

Year of fee payment: 5

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061122

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCAR

Free format text: SCHMAUDER & PARTNER AG PATENT- UND MARKENANWAELTE VSP;ZWAENGIWEG 7;8038 ZUERICH (CH)

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070103

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080103

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061122

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20090103

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070523

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061122

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090103

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090131

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090801

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090131

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20091030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090103

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20090105

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090202

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090105